```
=> fil reg
FILE 'REGISTRY' ENTERED AT 06:41:40 ON 05 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 JUL 2005  HIGHEST RN 853727-85-2
DICTIONARY FILE UPDATES:   4 JUL 2005  HIGHEST RN 853727-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from     *
* the IDE default display format and the ED field has been added,       *
* effective March 20, 2005.  A new display format, IDERL, is now        *
* available and contains the CA role and document type information.     *
*                                                                       *
*************************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d ide can l11

L11  ANSWER 1 OF 1 REGISTRY  COPYRIGHT 2005 ACS on STN
RN   150322-43-3  REGISTRY
ED   Entered STN:  29 Sep 1993
CN   Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-
     cyclopropyl-2-(2-fluorophenyl)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Thieno[3,2-c]pyridine, ethanone deriv.
OTHER NAMES:
CN   CS 747
CN   Prasugrel
FS   3D CONCORD
MF   C20 H20 F N O3 S
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, BIOSIS, CA, CAPLUS, CIN, IMSDRUGNEWS,
       IMSRESEARCH, IPA, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2,
       USPATFULL
```



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

17 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:441146

REFERENCE 2: 142:422831

REFERENCE 3: 141:428013

REFERENCE 4: 140:133861

REFERENCE 5: 139:207787

REFERENCE 6: 137:304829

REFERENCE 7: 137:263024

REFERENCE 8: 137:56780

REFERENCE 9: 137:52422

REFERENCE 10: 136:96057

=> d ide can l12 tot

L12 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 389574-20-3 REGISTRY
ED Entered STN: 05 Feb 2002
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H20 F N O3 S . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 150322-43-3
CMF C20 H20 F N O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:428013

REFERENCE 2: 139:207787

REFERENCE 3: 137:52422

REFERENCE 4: 136:96057

L12 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 389574-19-0 REGISTRY
ED Entered STN: 05 Feb 2002
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN LY 640315
CN Prasugrel hydrochloride
MF C20 H20 F N O3 S . Cl H
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
CRN (150322-43-3)




● HCl

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:428013

REFERENCE 2: 140:133861

REFERENCE 3: 139:207787

REFERENCE 4: 137:52422 .

REFERENCE 5: 136:96057

=> d ide can l13

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50-78-2** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-(Acetyloxy)benzoic acid
CN 2-Acetoxybenzoic acid
CN 2-Carboxyphenyl acetate
CN A.S.A. Empirin
CN AC 5230
CN Acenterine
CN Acesal
CN Acesan
CN Acetard
CN Aceticyl
CN Acetilum acidulatum
CN Acetisal
CN Acetol
CN Acetonyl
CN Acetophen
CN Acetosal
CN Acetosalic acid
CN Acetosalin
CN Acetylin
CN Acetylsal
CN Acetylsalicylic acid
CN Acetyonyl
CN Acetysal
CN Acidum acetylsalicylicum

CN Acimetten
CN Acisal
CN Acylpyrin
CN Adiro
CN Albyl E
CN ASA
CN Asaflow
CN Asagran
CN Asatard
CN Ascoden 30
CN Ascolong
CN Ascriptin
CN Aspalon
CN Aspergum
CN Aspirdrops
CN Aspirin
CN Aspirin Protect 100
CN Aspirin Protect 300
CN Aspirin-Direkt
CN Aspirina 03
CN Aspro
CN Aspro Clear
CN Aspropharm
CN Asteric
CN Bayer
CN Benaspir
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS 3D CONCORD
DR 11126-35-5, 11126-37-7, 98201-60-6, 2349-94-2, 26914-13-6
MF C9 H8 O4
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PATDPASPC, PDLCOM*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

18944 REFERENCES IN FILE CA (1907 TO DATE)
367 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
18965 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:32418

```
REFERENCE   2:  143:32417

REFERENCE   3:  143:32318

REFERENCE   4:  143:32254

REFERENCE   5:  143:32020

REFERENCE   6:  143:32019

REFERENCE   7:  143:26627

REFERENCE   8:  143:26590

REFERENCE   9:  143:21345

REFERENCE  10:  143:20034


=> d his

     (FILE 'HOME' ENTERED AT 06:18:37 ON 05 JUL 2005)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 06:18:48 ON 05 JUL 2005
L1             1 S US20040024013/PN OR (US2003-600266# OR WO2001-JP11201)/AP,PRN
L2         26955 S (SANKYO? OR UBE?)/PA,CS
               E ASAI F/AU
L3            78 S E3,E10
               E FUMITOSHI/AU
               E SUGIDACHI A/AU
L4            31 S E3,E5
               E ATSUHIRO S/AU
               E OGAWA T/AU
L5           776 S E3,E73
               E TAKETOSHI O/AU
               E INOUE T/AU
L6          1004 S E3-E5
               E INOUE TERU/AU
L7            66 S E6
               E TERUHIKO I/AU
L8             1 S E4
L9             5 S 2 ACETOXY 5 ALPHA CYCLOPROPYLCARBONYL 2 FLUOROBENZYL 4 5 6 7
               SEL RN L1

     FILE 'REGISTRY' ENTERED AT 06:22:54 ON 05 JUL 2005
L10            4 S E1-E4
L11            1 S L10 AND C20H20FNO3S AND 1/NC
L12            2 S 150322-43-3/CRN
L13            1 S 50-78-2
L14          508 S 50-78-2/CRN

     FILE 'HCAPLUS' ENTERED AT 06:24:24 ON 05 JUL 2005
L15           17 S L11 OR L12
L16           13 S CS747 OR CS 747 OR PRASUGREL OR LY640315 OR LY()(640315 OR 64
L17           21 S L9,L15,L16
L18        19865 S L13 OR L14
L19        27214 S ASPIRIN? OR (ACETYLSALICYLIC OR ACETYL SALICYLIC)()ACID OR AC
L20            7 S L17 AND L18,L19
```

```
L21           2 S L1-L8 AND L20
L22           7 S L20,L21
L23           4 S L22 AND (PY<=2001 OR PRY<=2001 OR AY<=2001)
L24           3 S L22 NOT L23
L25           5 S L21,L23

     FILE 'USPATFULL' ENTERED AT 06:31:05 ON 05 JUL 2005
L26          72 S L17
L27          64 S L26 AND (L18,L19)
L28          37 S L27 AND (PY<=2001 OR PRY<=2001 OR AY<=2001)

     FILE 'EMBASE' ENTERED AT 06:32:27 ON 05 JUL 2005
L29          24 S L17
L30          10 S L29 AND L18,L19
                E ASPIRIN/CT
                E E3+ALL
                E E2+ALL
L31       74966 S E1
L32          88 S ASPIRIN?/CT
L33          10 S L29 AND L31,L32
L34          10 S L30,L33
L35           0 S L34 AND PY<=2001

     FILE 'WPIX' ENTERED AT 06:34:03 ON 05 JUL 2005
L36           6 S L9/BIX OR L16/BIX
                E PRASUGREL/CN
L37           1 S E3
L38           4 S RA7RM2/DCN
L39           7 S L36,L38
L40        3676 S L19/BIX
                E ASPIRIN/DCN
                E E3+ALL
L41        2253 S E2 OR 0034/DRN
L42           2 S E4
L43           4 S E6
L44        1149 S E8
L45          16 S E10
L46           5 S L39 AND L40-L45
L47           1 S (2 ACETOXY 5 ALPHA CYCLOPROPYLCARBONYL 2 FLUROROBENZYL 4 5 6
L48           4 S L16/BI,ABEX,TI
L49           5 S L39,L47,L48 AND L40-L45
L50           5 S L46,L49
                SEL DN AN 1 3
L51           2 S L50 AND E1-E4

     FILE 'REGISTRY' ENTERED AT 06:41:40 ON 05 JUL 2005

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 06:42:02 ON 05 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
```

FILE COVERS 1907 - 5 Jul 2005 VOL 143 ISS 2
FILE LAST UPDATED: 4 Jul 2005 (20050704/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot l25

L25 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:480490 HCAPLUS
ED Entered STN: 07 Jun 2005
TI Pharmacology of **CS-747** (**prasugrel**, **LY640315**), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
AU Niitsu, Yoichi; Jakubowski, Joseph A.; **Sugidachi, Atsuhiro**; **Asai, Fumitoshi**
CS Pharmacology and Molecular Biology Research Laboratories, **Sankyo** Co., Ltd., Tokyo, Japan
SO Seminars in Thrombosis and Hemostasis (2005), 31(2), 184-194
CODEN: STHMBV; ISSN: 0094-6176
PB Thieme Medical Publishers, Inc.
DT Journal; General Review
LA English
CC 1 (Pharmacology)
AB **CS-747** (**prasugrel**, **LY640315**) is a member of the thienopyridine class of oral platelet aggregation inhibitors that includes ticlopidine and clopidogrel. A single oral administration of **CS-747** produced a dose-related inhibition of platelet aggregation in rats that was approx. 10- and 100-fold more potent than that of clopidogrel and ticlopidine, resp. The antiaggregatory effect of **CS-747** was evident at 30 min and lasted until 72 h after dosing, indicating fast onset and long duration of action. **CS-747** showed more potent antithrombotic activity compared with clopidogrel and ticlopidine with the same rank order as the antiaggregatory potencies. Combined administration of **CS-747** with **aspirin** to rats produced substantially greater inhibition of both platelet aggregation and thrombus formation compared with each agent alone. The antiplatelet action of **CS-747** is due to irreversible and selective blockade of platelet P2Y12 ADP (ADP) receptors by its active metabolite R-138727. In phase I studies, a single oral dose of **CS-747** (30 and 75 mg) produced > 50% inhibition of ADP-induced platelet aggregation, with rapid onset (1 h) and long duration (>48 h) of action. In healthy volunteers, once-daily administration of 10 mg **CS-747** for 10 days showed significant cumulative inhibition of platelet aggregation from 2 days after the first dose until at least 2 days after the final dose. Studies conducted to date indicate that **CS-747** is a highly effective antiplatelet and antithrombotic agent and is anticipated to be effective in the treatment of atherothrombotic and other ischemic vascular diseases.
ST review antiplatelet agent antithrombotic activity **prasugrel** thienopyridine **aspirin**; ticlopidine clopidogrel combination therapy
IT INDEXING IN PROGRESS

IT Combination chemotherapy
(**CS-747** alone or in combination with **aspirin** exhibited more potent antiplatelet activity and antithrombotic activity than ticlopidine and clopidogrel indicating that **CS-747** may be effective in treatment of atherothrombotic disease patient)
IT Human
(**CS-747** alone or with **aspirin** exhibited more potent and faster inhibition of platelet aggregation and thrombus formation than ticlopidine and clopidogrel indicating that **CS-747** may be used in treatment of atherothrombotic disease patient)
IT Platelet aggregation inhibitors
(**CS-747** either alone or with **aspirin** exhibited more potent inhibition of platelet aggregation than ticlopidine and clopidogrel indicating that **CS-747** may have therapeutic potential in treatment of patient with atherothrombotic disease)
IT Anticoagulants
(**CS-747** either alone or with **aspirin** exhibited more potent inhibition of thrombus formation than ticlopidine and clopidogrel indicating that **CS-747** may have therapeutic potential in treatment of patient with atherothrombotic disease)
IT Drug targets
(P2Y12 ADP receptor antagonist **CS-747** alone or with **aspirin** showed potent antiplatelet activity and antithrombotic activity than ticlopidine and clopidogrel indicating that **CS-747** may be used to treat atherothrombotic disease patient)
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Asai, F; J Thromb Haemost 2003, suppl, P2033
(2) Bennett, C; N Engl J Med 2000, V342, P1773 MEDLINE
(3) Boyer, J; Mol Pharmacol 1996, V50, P1323 HCAPLUS
(4) CAPRIE Steering Committee; Lancet 1996, V348, P1329
(5) Cattaneo, M; Thromb Res 1985, V37, P29 HCAPLUS
(6) Clarke, T; Drug Metab Dispos 2003, V31, P53 HCAPLUS
(7) Coukell, A; Drugs 1997, V54, P745 HCAPLUS
(8) Daniel, J; J Biol Chem 1998, V273, P2024 HCAPLUS
(9) Dejana, E; Thromb Res 1979, V15, P191 MEDLINE
(10) Di Minno, G; J Clin Invest 1985, V75, P328 HCAPLUS
(11) Ding, Z; Blood 2003, V101, P3908 HCAPLUS
(12) Dorsam, R; J Clin Invest 2004, V113, P340 HCAPLUS
(13) Gachet, C; Thromb Haemost 1997, V78, P271 HCAPLUS
(14) Gachet, C; Thromb Haemost 2001, V86, P222 HCAPLUS
(15) Gent, M; Lancet 1989, V1, P1215 MEDLINE
(16) George, J; Lancet 2000, V355, P1531 MEDLINE
(17) Hirota, T; Clin Pharmacol Ther 1999, V65, P148
(18) Hollopeter, G; Nature 2001, V409, P202 HCAPLUS
(19) Jackson, C; Blood 1992, V79, P1672 MEDLINE
(20) Jackson, S; Nat Rev Drug Discov 2003, V2, P775 HCAPLUS
(21) Jakubowski, J; J Thromb Haemost 2003, suppl, P2056
(22) Jaremo, P; J Intern Med 2002, V252, P233 MEDLINE
(23) Jarvis, B; Drugs 2000, V60, P347 MEDLINE
(24) Jin, J; J Biol Chem 1998, V273, P2030 HCAPLUS
(25) Kunapuli, S; Biochem J 1998, V336, P513 HCAPLUS
(26) Kunapuli, S; Platelets 1998, V9, P343 HCAPLUS
(27) Kunapuli, S; Trends Pharmacol Sci 1998, V19, P391 HCAPLUS
(28) Lau, W; Circulation 2003, V107, P32 HCAPLUS
(29) Lau, W; Circulation 2004, V109, P166 HCAPLUS

(30) McTavish, D; Drugs 1990, V40, P238 HCAPLUS
(31) Mitsios, J; Circulation 2004, V109, P1335 HCAPLUS
(32) Muller, I; Thromb Haemost 2003, V89, P783 HCAPLUS
(33) Page, Y; Lancet 1991, V337, P774 MEDLINE
(34) Peters, R; Circulation 2003, V108, P1682 HCAPLUS
(35) Quinn, M; Circulation 1999, V100, P1667 HCAPLUS
(36) Saltiel, E; Drugs 1987, V34, P222 HCAPLUS
(37) Savi, P; Thromb Haemost 2000, V84, P891 HCAPLUS
(38) Steinhubl, S; JAMA 1999, V281, P806 HCAPLUS
(39) Sugidachi, A; Br J Pharmacol 2000, V129, P1439 HCAPLUS
(40) Sugidachi, A; Br J Pharmacol 2001, V132, P47 HCAPLUS
(41) Sugidachi, A; J Thromb Haemost 2003, suppl, P2032
(42) Sugidachi, A; Thromb Res 1993, V69, P71 HCAPLUS
(43) Thebault, J; Semin Thromb Hemost 1999, V25(Suppl 2), P9
(44) Umetsu, T; Thromb Haemost 1978, V39, P74 HCAPLUS
(45) Vorchheimer, D; JAMA 1999, V281, P1407 HCAPLUS
(46) Zakarija, A; Stroke 2004, V35, P533

L25 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:813926 HCAPLUS
DN 137:304829
ED Entered STN: 25 Oct 2002
TI Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide
IN Hughes, David E.; Seidenberg, Beth C.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-422
ICS C07D413-12
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2002083130 | A1 | 20021024 | WO 2002-US11992 | 20020412 <-- |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2003040534 | A1 | 20030227 | US 2002-121520 | 20020412 <-- |
| PRAI | US 2001-284080P | P | 20010416 <-- | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| WO 2002083130 | ICM | A61K031-422 |
| | ICS | C07D413-12 |
| WO 2002083130 | ECLA | A61K031/422; A61K031/422+M; A61K045/06; C07D413/12+263B+261 <-- |
| US 2003040534 | NCL | 514/374.000; 548/235.000 |
| | ECLA | A61K031/422; A61K031/422+M; A61K045/06; C07D413/12+263B+261 <-- |

AB Endothelin antagonist N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino] sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide surprisingly exists as separable enantiomeric atropisomers. The (+)-dextrorotatory atropisomer demonstrates remarkably higher potency than either the (-)-levorotatory atropisomer or the racemate. The (+)-dextrorotatory atropisomer is suitable for treatment of endothelin-related disorders, such as hypertension, renal diseases, atherosclerosis, restenosis, congestive heart failure, diabetic nephropathy, cancer, asthma, etc., alone or in combination with, e.g., angiotensin, renin, or ACE inhibitors, diuretics, cardiac glycosides, antiplatelet agents, etc.

ST biphenyl isoxazole sulfonamide atropisomer endothelin antagonist

IT Angiotensin receptor antagonists
(angiotensin II, combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Prostate gland, disease
(benign hyperplasia; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Hyperplasia
(benign prostatic; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cardiac, combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Antiasthmatics
Diuretics
Platelet aggregation inhibitors
(combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Kidney, disease
(diabetic nephropathy; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Meninges
(disease, subarachnoid hemorrhage; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Heart, disease
(failure; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Artery, disease
(intermittent claudication; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Headache
(migraine; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Hypertension
(pulmonary; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Artery, disease
(restenosis; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Hemorrhage
(subarachnoid; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)

IT Asthma
Atherosclerosis
Endotoxemia
Hypertension
Ischemia
Kidney, disease

Neoplasm
(therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT 82707-54-8, Neutral endopeptidase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(-ACE dual inhibitors, combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT 116243-73-3, Endothelin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT 123626-67-5, Endothelin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(binding to; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT **50-78-2, Aspirin** 55142-85-3, Ticlopidine
113665-84-2, Clopidogrel **150322-43-3, CS 747**
160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT 9015-82-1, Angiotensin converting enzyme 9015-94-5, Renin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT 210891-04-6
RL: CPS (Chemical process); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process)
(therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT 472985-90-3P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT 472985-94-7, (-)-Edonentan
RL: PAC (Pharmacological activity); REM (Removal or disposal); BIOL (Biological study); PROC (Process)
(therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT 472985-91-4 472985-92-5 472985-93-6, (+)-Edonentan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Murugesan; US 6043265 A 2000 HCAPLUS
IT **50-78-2, Aspirin 150322-43-3, CS 747**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
RN 50-78-2 HCAPLUS
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)



RN 150322-43-3 HCAPLUS
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



L25 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:755214 HCAPLUS
DN 137:263024
ED Entered STN: 04 Oct 2002
TI Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
IN Murugesan, Natesan; Tellew, John E.; Macor, Jhon E.; Gu, Zhengxiang
PA Bristol-Myers Squibb Co., USA
SO U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S. Ser. No. 643,640, abandoned.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-4166
ICS A61K031-4184; A61K031-4196; C07D233-32; C07D213-68; C07D215-233; C07D249-08
INCL 514258000
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2002143024 | A1 | 20021003 | US 2000-737201 | 20001214 <-- |
| | US 6638937 | B2 | 20031028 | | |
| | US 2004106833 | A1 | 20040603 | US 2003-673100 | 20030926 <-- |
| | US 6835741 | B2 | 20041228 | | |
| | US 2004127515 | A1 | 20040701 | US 2003-672572 | 20030926 <-- |
| | US 6852745 | B2 | 20050208 | | |
| PRAI | US 1998-91847P | P | 19980706 <-- | | |
| | US 1999-345392 | B2 | 19990701 <-- | | |
| | US 1999-464037 | B2 | 19991215 <-- | | |
| | US 2000-481197 | B2 | 20000111 <-- | | |
| | US 2000-513779 | A2 | 20000225 <-- | | |
| | US 2000-604322 | A2 | 20000626 <-- | | |
| | US 2000-643640 | B2 | 20000822 <-- | | |
| | US 2000-737201 | A3 | 20001214 <-- | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| US 2002143024 | ICM | A61K031-4166 |
| | ICS | A61K031-4184; A61K031-4196; C07D233-32; C07D213-68; C07D215-233; C07D249-08 |
| | INCL | 514258000 |
| US 2002143024 | NCL | 514/255.050; 514/380.000; 514/385.000; 544/336.000; 548/245.000; 548/300.700 |
| | ECLA | C07D261/16; C07D401/12+231+215; C07D403/14+241B+235+207; C07D413/12+261+249B; C07D413/12+261+239; C07D413/12+261+231; C07D413/12+261+213; C07D413/12+261+235C; C07D413/12+261+233; C07D413/12+261+215; C07D413/12+261+235; C07D413/12+271+261; C07D413/12+307B+261; C07D413/14+261+249B+207; C07D413/14+261+213+207; C07D413/14+261+261+235; C07D413/14+261+241B+235; C07D413/14+261+235+233; C07D413/14+261+235+213; C07D413/14+261+235+207; C07D413/14+333B+261+235; C07D417/14+285B+261+235; C07D471/04+239B+221B; C07D471/04+235B+221B; C07D487/04+249C+231C <-- |
| US 2004106833 | NCL | 514/336.000; 514/340.000; 546/268.400; 546/272.100 |
| | ECLA | C07D261/16; C07D401/12+231+215; C07D403/14+241B+235+207; C07D413/12+261+213; C07D413/12+261+215; C07D413/12+261+231; C07D413/12+261+233; C07D413/12+261+235; C07D413/12+261+235C; C07D413/12+261+239; C07D413/12+261+249B; C07D413/12+271+261; C07D413/12+307B+261; C07D413/14+261+213+207; C07D413/14+261+235+207; C07D413/14+261+235+213; C07D413/14+261+235+233; C07D413/14+261+241B+235; C07D413/14+261+249B+207; C07D413/14+261+261+235; C07D413/14+333B+261+235; C07D417/14+285B+261+235; C07D471/04+235B+221B; C07D471/04+239B+221B; C07D487/04+249C+231C <-- |
| US 2004127515 | NCL | 514/380.000; 514/326.000; 514/340.000; 514/361.000; 514/364.000; 544/367.000; 546/209.000; 546/272.100; 548/131.000; 548/133.000; 548/245.000; 548/246.000 |
| | ECLA | C07D261/16; C07D401/12+231+215; C07D403/14+241B+235+207; C07D413/12+261+213; C07D413/12+261+215; C07D413/12+261+231; C07D413/12+261+233; C07D413/12+261+235; C07D413/12+261+235C; C07D413/12+261+239; C07D413/12+261+249B; C07D413/12+271+261; C07D413/12+307B+261; C07D413/14+261+213+207; C07D413/14+261+235+207; C07D413/14+261+235+213; C07D413/14+261+235+233; C07D413/14+261+241B+235; C07D413/14+261+249B+207; C07D413/14+261+261+235; C07D413/14+333B+261+235; C07D417/14+285B+261+235; C07D471/04+235B+221B; C07D471/04+239B+221B; C07D487/04+249C+231C <-- |
| OS | MARPAT 137:263024 | |
| GI | | |




I

AB Title compds. (I; R1 = specified oxoimidazolyl, pyridoimidazolyl, pyridylamino, pyridyloxy, triazolyl, quinolinyloxy, etc.; R2 = H, halo, CHO, (halo)alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; R101-R104 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, alkoxyalkoxy, cyano, OH, hydroxyalkyl, NO2, etc; with provisos) were prepared as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-BrC6H4CH2OH was coupled with [2-[[(4,5-dimethyl-3-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated to give the 4'-bromomethyl derivative (90%), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-[1,1'-biphenyl]-2-sulfonamide.

ST isoxazolyl biphenylsulfonamide prepn angiotensin endothelin receptor antagonist; diazaspirononenylmethyldimethylisoxazolylbiphenylsulfonamide prepn angiotensin endothelin receptor antagonist; antihypertensive biphenylsulfonamide prepn

IT Angiotensin receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(angiotensin II, antagonists; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Endothelin receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(antagonists; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Prostate gland, disease
(benign hyperplasia, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Hyperplasia
(benign prostatic, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT Meninges
(disease, subarachnoid hemorrhage, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT Sexual behavior
(disorder, treatment of female; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT Heart, disease
Kidney, disease
(failure, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT Sexual behavior
(impotence, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT Antiasthmatics
Antihypertensives
Antimigraine agents
Antitumor agents
Human
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT Growth inhibitors, animal
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT Artery, disease
(restenosis, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT Hemorrhage
(subarachnoid, treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT Atherosclerosis
Endotoxemia
Hypertension
Ischemia
(treatment; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT 62571-86-2, Captopril 74258-86-9, Alacepril 75847-73-3, Enalapril 76547-98-3, Lisinopril 81872-10-8, Zofenopril 82924-03-6, Pentopril 83435-66-9, Delapril 85441-61-8, Quinapril 87333-19-5, Ramipril 98048-97-6, Fosinopril 111223-26-8, Ceranapril 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
IT 254737-84-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254737-85-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(methylamino)methyl]- 254737-86-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl- 254737-87-6P, [1,1'-Biphenyl]-2-

sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254737-88-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254737-89-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-pyrazinyl- 254737-90-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3-chloropyrazinyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254737-91-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254737-92-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-(3,6-dimethylpyrazinyl)- 254737-94-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-(3-methoxypyrazinyl)- 254737-96-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-formyl- 254737-98-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254738-00-6P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- 254738-03-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254738-05-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(2-methoxyethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-06-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[2-(ethoxymethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254738-07-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254738-09-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254738-10-8P, Pentanamide, N-[[2'-[[(3-methyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254738-11-9P, Pentanamide, N-[[2'-[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254738-12-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-propyl- 254738-13-1P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254738-14-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254738-15-3P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester 254738-16-4P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- 254738-17-5P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-,methylester 254738-18-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254738-19-7P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-

isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- 254738-20-0P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- 254738-21-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)- 254738-22-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-imidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-23-3P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, methyl ester 254738-24-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N,N-dimethyl-2-propyl- 254738-25-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(hydroxymethyl)- 254738-26-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)- 254738-27-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-methoxyethyl)- 254738-28-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-(3-methoxy-5-methylpyrazinyl)- 254738-29-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4-bromo-3-methyl-5-isoxazolyl)-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254738-30-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(formylmethylamino)methyl]- 254738-31-3P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-32-4P, Cyclopropanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-33-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,2-dimethyl- 254738-34-6P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-35-7P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-methoxy-N-methyl- 254738-36-8P, 4-Pentynamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-37-9P, Cyclobutanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-38-0P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254738-39-1P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,2,2-trimethyl- 254738-40-4P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-methoxy-N-methyl- 254738-41-5P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-ethoxy-N-methyl- 254738-42-6P, 2-Furancarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-

2-yl]methyl]-N-methyl- 254738-43-7P, Pentanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,4-dimethyl- 254738-44-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-45-9P, 3-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-46-0P, Cyclopentaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-47-1P, Cyclohexanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-48-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254738-49-3P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-50-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-fluoro-N-methyl- 254738-51-7P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-fluoro-N-methyl- 254738-52-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-fluoro-N-methyl- 254738-53-9P, Cyclohexaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-54-0P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-fluoro-N-methyl- 254738-55-1P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-fluoro-N-methyl- 254738-56-2P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-fluoro-N-methyl- 254738-57-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(dimethylamino)carbonyl]methylamino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-58-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[[(1,1-dimethylethyl)amino]carbonyl]methylamino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-59-5P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, ethyl ester 254738-60-8P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, 2-methylpropyl ester 254738-61-9P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254738-62-0P, 2-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-63-1P, 3-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-64-2P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-

diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-65-3P, 1H-Pyrrole-2-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,1-dimethyl- 254738-66-4P, 1,2,3-Thiadiazole-4-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-67-5P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,5-dimethyl- 254738-68-6P, 4-Isoxazolecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3,5-trimethyl- 254738-69-7P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254738-70-0P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,5-dimethyl- 254738-71-1P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-cyano-N-methyl- 254738-72-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-cyano-N-methyl- 254738-73-3P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-methoxy-N-methyl- 254738-74-4P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-chloro-N-methyl- 254738-75-5P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-chloro-N-methyl- 254738-76-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-chloro-N-methyl- 254738-78-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2,3-difluoro-N-methyl- 254738-79-9P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3,4-difluoro-N-methyl- 254738-80-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3,5-difluoro-N-methyl- 254738-81-3P, Benzamide, 4-acetyl-N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254738-82-4P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-ethoxy-N-methyl- 254738-83-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254738-84-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(propylsulfonyl)amino]- 254738-85-7P, L-Valine, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)-, methyl ester 254738-86-8P, L-Valine, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- 254738-87-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(4-oxo-2-propyl-1,3-

diazaspiro[4.4]non-1-en-3-yl)methyl]- 254738-88-0P, Butanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254738-89-1P, Pentanamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254738-90-4P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254738-91-5P, Pentanamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254738-92-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254738-93-7P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]- 254738-94-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(trifluoromethyl)- 254738-95-9P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-, methyl ester 254738-96-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(methoxymethyl)- 254738-97-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro- 254738-98-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254738-99-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)- 254739-00-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)- 254739-01-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-methyl- 254739-02-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254739-03-2P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-04-3P
, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254739-05-4P, Benzeneacetamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]- 254739-06-5P, Butanamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]-3,3-dimethyl- 254739-07-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-amino-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-08-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-nitro- 254739-09-8P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-10-1P, Cyclopropanecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-11-2P, Benzenepropanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-12-3P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-

oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-13-4P, Hexanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254739-14-5P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254739-15-6P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,4-dimethyl-, (2S)- 254739-16-7P, Cyclopropanecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-17-8P, Benzenepropanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-18-9P, Benzeneacetamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-19-0P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254739-20-3P, Hexanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254739-21-4P, Pentanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254739-22-5P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S)- 254739-23-6P, Cyclopropanecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-24-7P, Benzenepropanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-25-8P, Benzeneacetamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-26-9P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-27-0P, Hexanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-28-1P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-29-2P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]- 254739-30-5P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(hexylamino)carbonyl]-2-methylpropyl]- 254739-31-6P, Pentanamide, N-[[2-cyano-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-32-7P, Pentanamide, N-[[2-(cyanomethyl)-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-33-8P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]- 254739-34-9P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N,N-dimethyl- 254739-35-0P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-methyl- 254739-36-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(methoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-37-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-

pyridinyl)oxy]methyl]-2'-methyl- 254739-38-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-methyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-39-4P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-40-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(hydroxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-41-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-42-9P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-fluoro[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-43-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(phenoxymethyl)- 254739-44-1P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(1H-pyrazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254739-45-2P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-46-3P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-, (2S)- 254739-47-4P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]- 254739-48-5P, Butanamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-,(2S) 254739-49-6P, Pentanamide, N-[[2-chloro-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-50-9P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-51-0P, Cyclobutanecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-52-1P, 1H-Imidazole-5-carboxylic acid, 1-[[2-chloro-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254739-53-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(methylsulfonyl)amino]- 254739-54-3P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(4-methyl-1-piperazinyl)carbonyl]propyl]- 254739-55-4P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(1-piperidinylcarbonyl)propyl]- 254739-56-5P, Pentanamide, N-[(1S)-1-[[(3,3-dimethylbutyl)amino]carbonyl]-2-methylpropyl]-N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-57-6P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-methylpropyl]-
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254739-58-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(1-methylethoxy)methyl]- 254739-59-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(propoxymethyl)- 254739-60-1P,

1H-Imidazole-5-carboxamide, 4-chloro-1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- 254739-61-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-62-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-oxo-1(2H)-pyridinyl)methyl]- 254739-63-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1H-pyrazol-1-ylmethyl)- 254739-64-5P, 1H-Imidazole-5-carboxamide, 2-butyl-4-chloro-1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254739-65-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-methyl-4-quinolinyl)oxy]methyl]- 254739-66-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254739-67-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-68-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-propyl-4-quinolinyl)oxy]methyl]- 254739-69-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-70-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254739-71-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254739-72-5P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- 254739-73-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester 254739-74-7P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester 254739-75-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester 254739-76-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 3-(2-oxo-1-pyrrolidinyl)propyl ester 254739-77-0P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254739-79-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-80-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254739-81-6P, 1H-Imidazole-5-carboxamide, 1-[[2-chloro-2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254739-82-7P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254739-83-8P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- 254739-84-9P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- 254739-85-0P, 3-Pyridinecarboxylic acid, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- 254739-86-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-87-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-

254739-88-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-89-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-6-[[[methyl(1-methylethyl)amino]carbonyl]amino]-4-oxo-3(4H)-quinazolinyl]methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-90-7P, 3-Pyridinecarboxamide, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- 254739-91-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254739-92-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254739-93-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254739-94-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- 254739-95-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-4-methyl- 254739-96-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-3(4H)-quinazolinyl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254739-97-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254739-98-5P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254739-99-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(4,4-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254740-00-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254740-01-7P, Acetamide, N-[2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]methylamino]ethyl]- 254740-02-8P, [1,1'-Biphenyl]-2-acetic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-, ethyl ester 254740-03-9P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(propylamino)carbonyl]propyl]- 254740-04-0P, Pentanamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]propyl]- 254740-05-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254740-06-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-2'-(trifluoromethyl)- 254740-07-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)- 254740-08-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-methylpropoxy)methyl]- 254740-09-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(ethylsulfonyl)amino]- 254740-10-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2,2,2-trifluoroethoxy)methyl]- 254740-11-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]- 254740-12-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254740-15-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-

2'-(ethoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254740-18-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(3,3,3-trifluoropropyl)- 254740-20-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-fluoropropyl)- 254740-21-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-isoxazolyl)- 254740-22-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2,2-trifluoroethyl)- 254740-23-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-methylpropoxy)- 254740-24-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-methoxyethoxy)- 254740-25-5P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254740-26-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)- 254740-27-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4-bromo-3-methyl-5-isoxazolyl)-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(trifluoromethyl)- 254740-28-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4-chloro-3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)- 254740-29-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(methoxymethylamino)methyl]- 254740-30-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(2,2-difluoroethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254740-31-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-fluoroethyl)- 254740-32-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-hydroxyethyl)- 254740-33-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-methylbutyl)- 254740-34-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-methylpropyl)- 254740-35-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(3,3-difluorobutyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)- 254740-36-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)- 254740-37-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)- 254740-38-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254740-39-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254740-40-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254740-41-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254740-42-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methylamino)methyl]- 254740-43-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-

en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254740-44-8P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- 254740-45-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254740-46-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-(2-methoxyethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254740-47-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[2-(ethoxymethyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254740-48-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254740-49-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254740-50-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl- 254740-51-7P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254740-52-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254740-53-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester 254740-54-0P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- 254740-55-1P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-,methylester 254740-56-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- 254740-57-3P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- 254740-58-4P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- 254740-59-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-N-(3-methyl-5-isoxazolyl)- 254740-60-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-imidazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-61-9P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, methyl ester 254740-62-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N,N-dimethyl-2-propyl- 254740-63-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(hydroxymethyl)- 254740-64-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)- 254740-65-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methoxyethyl)- 254740-66-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(formylmethylamino)methyl]- 254740-67-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-68-6P, Cyclopropanecarboxamide,

N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-69-7P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,2-dimethyl- 254740-70-0P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-71-1P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-methoxy-N-methyl- 254740-72-2P, 4-Pentynamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-73-3P, Cyclobutanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-74-4P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254740-75-5P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,2,2-trimethyl- 254740-76-6P, Propanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-methoxy-N-methyl- 254740-77-7P, Acetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-ethoxy-N-methyl- 254740-78-8P, 2-Furancarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-79-9P, Pentanamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,4-dimethyl- 254740-80-2P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-81-3P, 3-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-82-4P, Cyclopentaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-83-5P, Cyclohexanecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-84-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl- 254740-85-7P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-86-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-fluoro-N-methyl- 254740-87-9P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-fluoro-N-methyl- 254740-88-0P

, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-fluoro-N-methyl- 254740-89-1P, Cyclohexaneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254740-90-4P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-

isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-fluoro-N-methyl-
254740-91-5P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-fluoro-N-methyl-
254740-92-6P, Benzeneacetamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-fluoro-N-methyl-
254740-93-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[[(dimethylamino)carbonyl]methyla
mino]methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-94-8P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-2'-[[[[(1,1-dimethylethyl)amino]carbonyl]methylamino]methy
l]-N-(4,5-dimethyl-3-isoxazolyl)- 254740-95-9P, Carbamic acid,
[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-
dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-,
ethyl ester 254740-96-0P, Carbamic acid, [[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-,
2-methylpropyl ester 254740-97-1P, Butanamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl-
254740-98-2P, 2-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254740-99-3P, 3-Pyridinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254741-00-9P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254741-01-0P, 1H-Pyrrole-2-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,1-dimethyl-
254741-02-1P, 1,2,3-Thiadiazole-4-carboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl-
254741-03-2P, Pyrazinecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,5-dimethyl-
254741-04-3P, 4-Isoxazolecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3,5-trimethyl-
254741-05-4P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,3-dimethyl-
254741-06-5P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N,5-dimethyl-
254741-07-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-
3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-2-yl]methyl]-3-cyano-N-methyl- 254741-08-7P, Benzamide,
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-
dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-cyano-
N-methyl- 254741-09-8P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-
diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2-methoxy-N-methyl-
254741-10-1P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-
3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-
biphenyl]-2-yl]methyl]-2-chloro-N-methyl- 254741-11-2P, Benzamide,
N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-

dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-chloro-N-methyl- 254741-12-3P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-4-chloro-N-methyl- 254741-13-4P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-2,3-difluoro-N-methyl- 254741-14-5P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3,4-difluoro-N-methyl- 254741-15-6P, Benzamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3,5-difluoro-N-methyl- 254741-16-7P, Benzamide, 4-acetyl-N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-N-methyl- 254741-17-8P, 2-Thiophenecarboxamide, N-[[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]-3-ethoxy-N-methyl- 254741-19-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(propylsulfonyl)amino]- 254741-20-3P, L-Valine, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)-, methyl ester 254741-22-5P, L-Valine, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- 254741-24-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(4-oxo-2-propyl-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]- 254741-26-9P, Butanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethyl- 254741-27-0P, Pentanamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254741-28-1P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-30-5P, Pentanamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254741-31-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254741-32-7P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]- 254741-33-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(trifluoromethyl)- 254741-34-9P, [1,1'-Biphenyl]-2-carboxylic acid, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-, methyl ester 254741-35-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(methoxymethyl)- 254741-36-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-fluoro-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254741-37-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254741-38-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-

(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)- 254741-39-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)- 254741-40-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-methyl- 254741-41-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- 254741-42-9P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-43-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-[[(2,2,2-trifluoroethyl)amino]methyl]- 254741-44-1P, Benzeneacetamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]- 254741-45-2P, Butanamide, N-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-2-yl]-3,3-dimethyl- 254741-46-3P, [1,1'-Biphenyl]-2-sulfonamide, 2'-amino-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254741-48-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-nitro- 254741-50-9P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-52-1P, Cyclopropanecarboxamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-54-3P, Benzenepropanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-56-5P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-58-7P, Hexanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S,2S)-2-methyl-1-[(methylamino)carbonyl]butyl]- 254741-60-1P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S,3S)- 254741-62-3P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,4-dimethyl-, (2S)- 254741-64-5P, Cyclopropanecarboxamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-66-7P, Benzenepropanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-68-9P, Benzeneacetamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-70-3P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](3-methyl-1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254741-72-5P, Hexanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-3-methyl-1-[(methylamino)carbonyl]butyl]- 254741-74-7P, Pentanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,4-dimethyl-, (2S)- 254741-76-9P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxopropyl)amino]-N,3-dimethyl-, (2S)- 254741-78-1P, Cyclopropanecarboxamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-80-5P, Benzenepropanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-

[(methylamino)carbonyl]propyl]- 254741-82-7P, Benzeneacetamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-85-0P, Butanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-methyl-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-87-2P, Hexanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-89-4P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254741-91-8P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]- 254741-93-0P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[(hexylamino)carbonyl]-2-methylpropyl]- 254741-95-2P, Pentanamide, N-[[2-cyano-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-97-4P, Pentanamide, N-[[2-(cyanomethyl)-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254741-99-6P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]- 254742-01-3P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-N,N-dimethyl- 254742-03-5P, [1,1'-Biphenyl]-2-carboxamide, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-N-methyl- 254742-05-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(methoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-06-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-methyl- 254742-07-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-methyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-08-0P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254742-09-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(hydroxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-10-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254742-11-5P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-fluoro[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254742-12-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(phenoxymethyl)- 254742-13-7P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(1H-pyrazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,3-dimethyl-, (2S)- 254742-14-8P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254742-15-9P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-, (2S)- 254742-16-0P, Cyclopropanecarboxamide, N-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]- 254742-17-1P, Butanamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl](1-oxobutyl)amino]-N,N,3-trimethyl-,(2S) 254742-18-2P, Pentanamide, N-[[2-chloro-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-

2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-19-3P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-20-6P, Cyclobutanecarboxamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-21-7P, 1H-Imidazole-5-carboxylic acid, 1-[[2-chloro-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254742-22-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methylsulfonyl)amino]- 254742-23-9P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(4-methyl-1-piperazinyl)carbonyl]propyl]- 254742-24-0P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-(1-piperidinylcarbonyl)propyl]- 254742-25-1P, Pentanamide, N-[(1S)-1-[[(3,3-dimethylbutyl)amino]carbonyl]-2-methylpropyl]-N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254742-28-4P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-1-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-methylpropyl]- 254742-29-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(1-methylethoxy)methyl]- 254742-31-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(propoxymethyl)- 254742-33-1P, 1H-Imidazole-5-carboxamide, 4-chloro-1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- 254742-35-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-fluoro-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-36-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-oxo-1(2H)-pyridinyl)methyl]- 254742-37-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1H-pyrazol-1-ylmethyl)- 254742-38-6P, 1H-Imidazole-5-carboxamide, 2-butyl-4-chloro-1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- 254742-39-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-methyl-4-quinolinyl)oxy]methyl]- 254742-41-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-43-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254742-45-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-propyl-4-quinolinyl)oxy]methyl]- 254742-46-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-47-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-49-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]- 254742-51-3P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- 254742-53-5P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester 254742-54-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester 254742-56-8P, 1H-Benzimidazole-7-carboxylic acid,

1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester 254742-58-0P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 3-(2-oxo-1-pyrrolidinyl)propyl ester 254742-60-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-62-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(cyanomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-64-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254742-65-9P, 1H-Imidazole-5-carboxamide, 1-[[2-chloro-2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254742-66-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254742-67-1P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- 254742-68-2P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- 254742-69-3P, 3-Pyridinecarboxylic acid, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]- 254742-70-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-71-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-72-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-73-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-butyl-6-[[[methyl(1-methylethyl)amino]carbonyl]amino]-4-oxo-3(4H)-quinazolinyl]methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-75-1P, 3-Pyridinecarboxamide, 2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]propylamino]-N-methyl- 254742-76-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254742-77-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254742-78-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-79-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(methoxymethyl)- 254742-80-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-4-methyl- 254742-81-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-3(4H)-quinazolinyl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254742-82-0P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254742-83-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(4,4-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254742-84-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]- 254742-85-3P, Acetamide, N-[2-[[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]methyl]methylamino]ethyl]- 254742-86-4P

, [1,1'-Biphenyl]-2-acetic acid, 2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-

b]pyridin-3-yl)methyl]-, ethyl ester 254742-87-5P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(propylamino)carbonyl]propyl]- 254742-88-6P, Pentanamide, N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]propyl]- 254742-89-7P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254742-91-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]-2'-(trifluoromethyl)- 254742-92-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-chloro-N-(4,5-dimethyl-3-isoxazolyl)- 254742-93-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-methylpropoxy)methyl]- 254742-94-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(ethylsulfonyl)amino]- 254742-95-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2,2,2-trifluoroethoxy)methyl]- 254742-96-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]- 254742-97-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254742-98-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254742-99-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3,3,3-trifluoropropyl)- 254743-00-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3-fluoropropyl)- 254743-01-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-(1,1-difluoroethyl)-N-(4,5-dimethyl-3-isoxazolyl)- 254743-03-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2,2-trifluoroethyl)- 254743-05-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methylpropoxy)- 254743-06-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methoxyethoxy)- 254743-08-3P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-10-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-[(methoxymethylamino)methyl]- 254743-12-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(2,2-difluoroethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-15-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-fluoroethyl)- 254743-16-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-hydroxyethyl)- 254743-17-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(3-methylbutyl)- 254743-18-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-methylpropyl)- 254743-19-6P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(3,3-difluorobutyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)- 254743-20-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-

pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)- 254743-22-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)- 254743-24-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254743-25-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(methoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254743-26-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254743-27-6P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254743-28-7P 254743-29-8P 254743-30-1P 254743-31-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl- 254743-32-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)- 254743-33-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)- 254743-34-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-35-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-36-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-37-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-38-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-39-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-40-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-41-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-42-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-ethyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-43-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-44-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-45-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-46-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-ethyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-47-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2,2-dimethylpropyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-48-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(2-ethoxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-49-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-50-5P 254743-51-6P 254743-53-8P 254743-56-1P,

[1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-57-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-58-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(tetrahydro-2-furanyl)- 254743-59-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-61-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-62-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(tetrahydro-2-furanyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-63-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)- 254743-64-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)- 254743-65-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(tetrahydro-2-furanyl)- 254743-66-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-67-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-68-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(tetrahydro-2-furanyl)- 254743-69-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxyethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-70-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(1-hydroxy-1-methylethyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-71-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(tetrahydro-2-furanyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-72-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-2'-(3,3,3-trifluoropropyl)- 254743-73-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-2'-(3,3,3-trifluoropropyl)- 254743-74-3P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- 254743-75-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-propyl- 254743-76-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-77-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-propyl-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]-

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 254743-78-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-79-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-80-1P, [1,1'-Biphenyl]-2-

sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-81-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(2-fluoroethoxy)methyl]-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-82-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[2-(2,2-difluorobutyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-propyl- 254743-83-4P 254743-84-5P 254743-85-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[4-oxo-2-(4,4,4-trifluorobutyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254743-86-7P 254743-87-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[4-oxo-2-(4,4,4-trifluorobutyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-2'-propyl- 254743-88-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-[[4-oxo-2-(3,3,3-trifluoropropyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]- 254743-89-0P 254743-90-3P 254743-91-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-[[4-oxo-2-(3,3,3-trifluoropropyl)-1,3-diazaspiro[4.4]non-1-en-3-yl]methyl]-2'-propyl- 254743-92-5P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-93-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]- 254743-94-7P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(4,5-dimethyl-3-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-95-8P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoropropyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-[(5,6,7,8-tetrahydro-8-oxo-2-propyl-1(4H)-cycloheptimidazolyl)methyl]- 254743-96-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(1,1,3,3,3-pentafluoropropyl)- 254743-97-0P 254743-98-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254743-99-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-00-8P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-01-9P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-02-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-03-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-04-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-05-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-06-4P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-07-5P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-08-6P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl- 254744-09-7P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-N-methyl-2-propyl-

254744-10-0P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-11-1P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-propyl[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-12-2P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(2-fluoroethoxy)methyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl- 254744-13-3P, 1H-Imidazole-5-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-(ethoxymethyl)[1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl-
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 56-12-2, 4-Aminobutyric acid, reactions 75-03-6, Iodoethane 78-09-1, Tetraethyl orthocarbonate 79-03-8, Propionyl chloride 79-44-7, Dimethylcarbamyl chloride 95-89-6, 2-Chloro-3,6-dimethylpyrazine 109-81-9, N-Methylethylenediamine 124-40-3, Dimethylamine, reactions 127-08-2, Potassium acetate 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl chloroformate 589-15-1, 4-Bromobenzyl bromide 627-03-2, Ethoxyacetic acid 638-29-9, Valeryl chloride 676-58-4, Methylmagnesium chloride 680-15-9, Acetic acid, difluoro(fluorosulfonyl)-, methyl ester 767-00-0, 4-Cyanophenol 865-33-8, Potassium methoxide 873-75-6, 4-Bromobenzyl alcohol 1117-97-1, N-Methoxy-N-methylamine 1122-91-4, 4-Bromobenzaldehyde 1450-75-5, Ethanone, 1-(5-bromo-2-hydroxyphenyl)- 1530-32-1, Ethyltriphenylphosphonium bromide 1609-86-5, tert-Butyl isocyanate 2835-98-5, Phenol, 2-amino-5-methyl- 2905-25-1, 2-Bromobenzenesulfonyl chloride 3959-07-7, 4-Bromobenzylamine 4858-85-9, 2,3-Dichloropyrazine 5326-34-1, 4-Bromo-3-nitrotoluene 6228-47-3, Propyltriphenylphosphonium bromide 6482-24-2, 1-Bromo-2-methoxyethane 13734-41-3, L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- 14508-49-7, 2-Chloropyrazine 14678-02-5, 5-Amino-3-methylisoxazole 22059-22-9, Acetamide oxime 22884-29-3, Isobutyltriphenylphosphonium bromide 28466-21-9, 4-Amino-1,3,5-trimethylpyrazole 29006-02-8, Butanoic acid, 4-methoxy- 33670-32-5, Methoxymethyltriphenylphosphonium bromide 34328-47-7, Benzaldehyde, 4-bromo-3-(trifluoromethyl)- 34841-06-0, 3-Bromo-4-methoxybenzaldehyde 40155-28-0, 2-Chloro-3-methoxypyrazine 41963-20-6, 4-Bromo-3-methylbenzonitrile 53553-14-3, Methyl 2-chloro-3-nitrobenzoate 53596-60-4, Benzoic acid, 4-hydroxy-3-(2-propenyl)-, methyl ester 60421-23-0, Cyclopentanecarboxylic acid, 1-amino-, methyl ester, hydrochloride 74410-26-7, Butanamide, 2-amino-N,3-dimethyl-, monohydrochloride, (2S)- 76513-69-4, 2-(Trimethylsilyl)ethoxymethyl chloride 78775-11-8, Benzaldehyde, 4-bromo-3-methyl- 87199-17-5, 4-Formylphenylboronic acid 89464-87-9, 2-Amino-3-methoxy-5-methylpyrazine 98946-18-0, tert-Butyl 2,2,2-trichloroacetimidate 109072-25-5, 4(1H)-Quinolinone, 2-ethyl- 120077-69-2, Benzaldehyde, 4-bromo-3-chloro- 124750-49-8, 1H-Imidazole-4-carboxaldehyde, 5-chloro-2-propyl- 125110-82-9, 4,4-Difluoropentanoic acid 133059-43-5, Benzaldehyde, 4-bromo-3-fluoro- 133240-06-9, 1H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl- 138402-05-8, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl- 148547-19-7, Methyl 4-bromo-3-methylbenzoate 150691-04-6, Boronic acid, [2-[[(1,1-dimethylethyl)amino]sulfonyl]phenyl]- 151257-01-1, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-, monohydrochloride 153039-15-7, Butanoic acid, 4-amino-2,2-dimethyl-, hydrochloride 160313-50-8, Benzonitrile, 4-bromo-3-(1,3-dioxolan-2-yl)- 162647-41-8, 4-Pyridinol, 3-methoxy-2,6-dimethyl- 167985-34-4, 1H-Imidazole-4-carboxylic acid, 5-ethyl-2-propyl-, ethyl ester 176961-13-0, Boronic acid, [2-[[(3,4-dimethyl-5-isoxazolyl)[(2-

methoxyethoxy)methyl]amino]sulfonyl]phenyl]- 195436-86-3, Benzenesulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 254746-77-5, Boronic acid, [2-[[(4,5-dimethyl-3-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]- 254746-78-6, Butanoic acid, 4-amino-2,2-dimethyl-, ethyl ester, hydrochloride 254746-79-7, Boronic acid, [2-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]phenyl]- 254746-80-0, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-(ethoxymethyl)-N-[(2-methoxyethoxy)methyl]- 254746-81-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT 14847-51-9P, Phenol, 2-bromo-5-methyl- 79047-47-5P, 1H-Imidazole-4-methanol, 5-chloro-2-propyl- 89003-95-2P, Benzonitrile, 4-bromo-3-formyl- 123652-98-2P, Benzene, 2-bromo-4-(dimethoxymethyl)-1-methoxy- 142031-67-2P, Benzoic acid, 4-bromo-3-(bromomethyl)-, methyl ester 160313-48-4P, Benzenemethanol, 4-bromo-3-(1,3-dioxolan-2-yl)- 176961-30-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]- 189762-06-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]- 189762-08-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl- 190197-86-5P, Benzonitrile, 4-bromo-3-(bromomethyl)- 254744-14-4P, Benzonitrile, 3-[(acetyloxy)methyl]-4-bromo- 254744-15-5P, Benzaldehyde, 4-bromo-3-(hydroxymethyl)- 254744-16-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-17-7P, Benzonitrile, 4-bromo-3-(methoxymethyl)- 254744-18-8P, Benzaldehyde, 4-bromo-3-(methoxymethyl)- 254744-19-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-(methoxymethyl)- 254744-20-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-(methoxymethyl)- 254744-21-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(methoxymethyl)- 254744-22-4P, [1,1'-Biphenyl]-2-sulfonamide, 2'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-23-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-24-6P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-25-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-26-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-methyl- 254744-27-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro-4'-formyl-N-[(2-methoxyethoxy)methyl]- 254744-28-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-29-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-30-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-fluoro-N-[(2-methoxyethoxy)methyl]- 254744-31-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-32-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-methyl-4'-[[(methylsulfonyl)oxy]methyl]- 254744-33-7P,

[1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(hydroxymethyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-34-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-methyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-35-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-36-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-37-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-2'-(methoxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254744-38-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-39-3P 254744-40-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-41-7P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(4,5-dimethyl-3-isoxazolyl)-N-[(2-methoxyethoxy)methyl]- 254744-42-8P 254744-43-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-N-[(2-methoxyethoxy)methyl]- 254744-44-0P, [1,1'-Biphenyl]-2-sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-[(methylamino)methyl]- 254744-45-1P, Carbamic acid, [[4-cyano-2'-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, 1,1-dimethylethyl ester 254744-46-2P, Carbamic acid, [[2'-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]-4-formyl[1,1'-biphenyl]-2-yl]methyl]methyl-, 1,1-dimethylethyl ester 254744-47-3P, Carbamic acid, [[4-(bromomethyl)-2'-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl][1,1'-biphenyl]-2-yl]methyl]methyl-, 1,1-dimethylethyl ester 254744-48-4P 254744-49-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-cyano-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl]- 254744-50-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-4'-formyl-N-[(2-methoxyethoxy)methyl]- 254744-51-9P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-2'-(1,3-dioxolan-2-yl)-N-[(2-methoxyethoxy)methyl]- 254744-52-0P 254744-53-1P, Benzaldehyde, 4-bromo-3-(1,3-dioxolan-2-yl)- 254744-54-2P, 1,3-Dioxolane, 2-[2-bromo-5-(bromomethyl)phenyl]- 254744-55-3P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(1,3-dioxolan-2-yl)phenyl]methyl]-2-butyl- 254744-56-4P 254744-58-6P 254744-60-0P 254744-63-3P 254744-65-5P 254744-68-8P 254744-70-2P 254744-73-5P, 1,2,4-Oxadiazole-5-methanamine, 3-methyl-α-(1-methylethyl)-, (αS)- 254744-78-0P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[[(1S)-2-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]amino]methyl]- 254744-81-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]- 254744-84-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]- 254744-86-0P, Cyclopentanecarboxylic acid, 1-[(3-methoxy-1-oxopropyl)amino]-, methyl ester 254744-87-1P, Cyclopentanecarboxylic acid, 1-[(3-methoxy-1-oxopropyl)amino]- 254744-90-6P, Cyclopentanecarboxamide, 1-[(3-methoxy-1-oxopropyl)amino]- 254744-91-7P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(2-methoxyethyl)- 254744-95-1P, Cyclopentanecarboxylic acid, 1-[(ethoxyacetyl)amino]-, methyl ester 254744-98-4P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(ethoxymethyl)- 254745-00-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-formyl-N-[(2-methoxyethoxy)methyl]-4'-[(methylsulfonyl)oxy]- 254745-03-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2'-formyl-

N-[(2-methoxyethoxy)methyl]- 254745-06-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(2-oxo-1-pyrrolidinyl)methyl]- 254745-08-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[(2-methoxyethoxy)methyl]-2'-[(3-methyl-2-oxo-1-imidazolidinyl)methyl]- 254745-12-5P, Benzenesulfonamide, 2-bromo-N-(3-methyl-5-isoxazolyl)- 254745-14-7P, Benzenesulfonamide, 2-bromo-N-(3-methyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-19-2P, [1,1'-Biphenyl]-2-sulfonamide, 4'-formyl-N-(3-methyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-23-8P, Butanamide, N,3-dimethyl-2-[[[2'-[[(3-methyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-, (2S)- 254745-28-3P, Pentanamide, N-[[2'-[[(3-methyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(1S)-2-methyl-1-[(methylamino)carbonyl]propyl]- 254745-31-8P, Benzonitrile, 4-bromo-3-(1-propenyl)- 254745-36-3P, Benzonitrile, 4-bromo-3-propyl- 254745-39-6P, Benzaldehyde, 4-bromo-3-propyl- 254745-42-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-propyl- 254745-43-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-propyl- 254745-45-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-4'-[[(methylsulfonyl)oxy]methyl]-2'-propyl- 254745-46-5P 254745-48-7P, Benzoic acid, 2-[[(4-bromophenyl)methyl]amino]-3-nitro-, methyl ester 254745-49-8P, Benzoic acid, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-nitro-, methyl ester 254745-50-1P, Benzoic acid, 3-amino-2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester 254745-51-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254745-52-3P, Benzenemethanamine, 4-bromo-3-(1,3-dioxolan-2-yl)- 254745-53-4P, Benzoic acid, 2-[[[4-bromo-3-(1,3-dioxolan-2-yl)phenyl]methyl]amino]-3-nitro-, methyl ester 254745-54-5P, Benzoic acid, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-formyl[1,1'-biphenyl]-4-yl]methyl]amino]-3-nitro-, methyl ester 254745-55-6P, Benzoic acid, 2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]amino]-3-nitro-, methyl ester 254745-57-8P, Benzoic acid, 3-amino-2-[[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester 254745-58-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254745-60-3P, Quinoline, 4-[(4-bromophenyl)methoxy]-2-ethyl- 254745-61-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(1,1-dimethylethyl)-4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254745-62-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254745-64-7P, [1,1'-Biphenyl]-2-sulfonic acid, 4'-[[(2-ethyl-4-quinolinyl)oxy]methyl]- 254745-66-9P, Ethanone, 1-(5-chloro-2-propyl-1H-imidazol-4-yl)- 254745-68-1P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(5-acetyl-4-chloro-2-propyl-1H-imidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-70-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-[(4-chloro-5-formyl-2-propyl-1H-imidazol-1-yl)methyl]-N-

(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-
254745-72-7P, 1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[(3,4-
dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfony
l][1,1'-biphenyl]-4-yl]methyl]-2-propyl- 254745-73-8P,
1H-Imidazole-5-carboxylic acid, 4-chloro-1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-
254745-76-1P, 1H-Imidazole-5-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl][1,1'-biphenyl]-4-
yl]methyl]-4-ethyl-2-propyl-, ethyl ester 254745-77-2P,
1H-Imidazole-5-carboxylic acid, 1-[[2'-[[(3,4-dimethyl-5-
isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-4-ethyl-2-propyl-
254745-78-3P 254745-79-4P 254745-80-7P 254745-81-8P 254745-82-9P,
Benzenesulfonamide, 2-bromo-N-(3-methoxy-5-methylpyrazinyl)-
254745-83-0P, Benzenesulfonamide, 2-bromo-N-(3-methoxy-5-methylpyrazinyl)-
N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-84-1P 254745-85-2P,
[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-
en-3-yl)methyl]-2'-formyl-N-(3-methoxy-5-methylpyrazinyl)- 254745-86-3P,
Benzenesulfonamide, 2-bromo-N-[(2-methoxyethoxy)methyl]-N-(3-methyl-5-
isoxazolyl)- 254745-87-4P, Boronic acid, [2-[[[(2-
methoxyethoxy)methyl](3-methyl-5-isoxazolyl)amino]sulfonyl]phenyl]-
254745-88-5P 254745-89-6P 254745-90-9P 254745-91-0P, Benzene,
4-(dimethoxymethyl)-1-methoxy-2-(3,3,3-trifluoropropyl)- 254745-92-1P,
Benzaldehyde, 4-methoxy-3-(3,3,3-trifluoropropyl)- 254745-93-2P,
Benzaldehyde, 4-hydroxy-3-(3,3,3-trifluoropropyl)- 254745-94-3P,
Methanesulfonic acid, trifluoro-, 4-formyl-2-(3,3,3-trifluoropropyl)phenyl
ester 254745-95-4P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-
isoxazolyl)-4'-formyl-2'-(3,3,3-trifluoropropyl)-N-[[2-
[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-96-5P, [1,1'-Biphenyl]-2-
sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-(3,3,3-
trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254745-97-6P
254745-98-7P, Benzoic acid, 3-(2-propenyl)-4-[[(trifluoromethyl)sulfonyl]o
xy]-, methyl ester 254745-99-8P, Benzoic acid, 3-(3-hydroxypropyl)-4-
[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester 254746-00-4P,
[1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-
[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(3-hydroxypropyl)-,
methyl ester 254746-01-5P, [1,1'-Biphenyl]-4-carboxylic acid,
2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]ami
no]sulfonyl]-2-(3-fluoropropyl)-, methyl ester 254746-03-7P,
[1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(3-
fluoropropyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-
254746-04-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-
isoxazolyl)-2'-(3-fluoropropyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-
[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-06-0P 254746-07-1P,
Methanesulfonic acid, trifluoro-, 2-acetyl-4-bromophenyl ester
254746-08-2P, Methanesulfonic acid, trifluoro-, 4-bromo-2-(1,1-
difluoroethyl)phenyl ester 254746-09-3P, Methanesulfonic acid,
trifluoro-, 2-(1,1-difluoroethyl)-4-formylphenyl ester 254746-10-6P,
[1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-
isoxazolyl)-4'-formyl-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-
254746-11-7P, [1,1'-Biphenyl]-2-sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-
dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-
[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-12-8P, [1,1'-Biphenyl]-2-
sulfonamide, 2'-(1,1-difluoroethyl)-N-(3,4-dimethyl-5-isoxazolyl)-4'-
[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]-
254746-13-9P 254746-14-0P, Benzoic acid, 4-bromo-3-(2,2,2-
trifluoroethyl)-, methyl ester 254746-15-1P, [1,1'-Biphenyl]-4-
carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-
[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(2,2,2-
trifluoroethyl)-, methyl ester 254746-16-2P, [1,1'-Biphenyl]-2-
sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-(2,2,2-

trifluoroethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-18-4P 254746-19-5P, Benzene, 1-bromo-4-methyl-2-(2-methylpropoxy)- 254746-20-8P, Benzene, 1-bromo-4-(bromomethyl)-2-(2-methylpropoxy)- 254746-21-9P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(2-methylpropoxy)phenyl]methyl]-2-butyl- 254746-22-0P 254746-23-1P, Benzene, 1-bromo-2-(2-methoxyethoxy)-4-methyl- 254746-24-2P, Benzene, 1-bromo-4-(bromomethyl)-2-(2-methoxyethoxy)- 254746-25-3P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(2-methoxyethoxy)phenyl]methyl]-2-butyl- 254746-26-4P 254746-27-5P, Benzonitrile, 4-bromo-3-(1-butenyl)- 254746-28-6P, Benzonitrile, 4-bromo-3-butyl- 254746-29-7P, Benzaldehyde, 4-bromo-3-butyl- 254746-30-0P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-31-1P, [1,1'-Biphenyl]-2-sulfonamide, 2'-butyl-N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(methylsulfonyl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-32-2P 254746-33-3P, Boronic acid, [2-[[(3-methyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]phenyl]- 254746-34-4P, [1,1'-Biphenyl]-2-sulfonamide, 4'-formyl-N-(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-35-5P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(hydroxymethyl)-N-(3-methyl-5-isoxazolyl)-2'-(trifluoromethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-36-6P 254746-37-7P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-[(methoxymethylamino)methyl]- 254746-38-8P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-[(methoxymethylamino)methyl]- 254746-39-9P 254746-40-2P, Benzoic acid, 4-bromo-3-(hydroxymethyl)-, methyl ester 254746-41-3P, Benzoic acid, 3-[(acetyloxy)methyl]-4-bromo-, methyl ester 254746-42-4P, Benzoic acid, 4-bromo-3-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-, methyl ester 254746-43-5P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-, methyl ester 254746-44-6P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-45-7P 254746-46-8P 254746-47-9P 254746-48-0P, Benzoic acid, 3-(2-hydroxyethyl)-4-[[(trifluoromethyl)sulfonyl]oxy]-, methyl ester 254746-49-1P , [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(2-hydroxyethyl)-, methyl ester 254746-50-4P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-(2-fluoroethyl)-, methyl ester 254746-51-5P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-(2-fluoroethyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-52-6P 254746-53-7P, [1,1'-Biphenyl]-4-carboxylic acid, 2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-, methyl ester 254746-54-8P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-2'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-55-9P, Benzonitrile, 4-bromo-3-(3-methyl-1-butenyl)- 254746-56-0P, Benzonitrile, 4-bromo-3-(3-methylbutyl)- 254746-57-1P, Benzaldehyde, 4-bromo-3-(3-methylbutyl)- 254746-58-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-(3-methylbutyl)- 254746-59-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(3-methylbutyl)- 254746-60-6P, Benzonitrile, 4-[(2-methyl-2-propenyl)oxy]- 254746-61-7P,

Benzonitrile, 4-hydroxy-3-(2-methyl-2-propenyl)- 254746-62-8P, Benzonitrile, 4-hydroxy-3-(2-methylpropyl)- 254746-63-9P, Benzaldehyde, 4-hydroxy-3-(2-methylpropyl)- 254746-64-0P, Methanesulfonic acid, trifluoro-, 4-formyl-2-(2-methylpropyl)phenyl ester 254746-65-1P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-formyl-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-66-2P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-67-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-2'-(2-methylpropyl)- 254746-68-4P 254746-69-5P, Cyclopentanecarboxylic acid, 1-[(3,3-difluoro-1-oxobutyl)amino]-, methyl ester 254746-70-8P, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-(3,3-difluorobutyl)- 254746-71-9P, [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-[[(3-methoxy-2,6-dimethyl-4-pyridinyl)oxy]methyl]-2'-(3,3,3-trifluoropropyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-72-0P, Benzoic acid, 4-bromo-3-[(1,1-dimethylethoxy)methyl]-, methyl ester 254746-73-1P, [1,1'-Biphenyl]-4-carboxylic acid, 2-[(1,1-dimethylethoxy)methyl]-2'-[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-, methyl ester 254746-74-2P, [1,1'-Biphenyl]-2-sulfonamide, 2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(hydroxymethyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-75-3P, [1,1'-Biphenyl]-2-sulfonamide, 4'-(bromomethyl)-2'-[(1,1-dimethylethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-N-[[2-[(trimethylsilyl)oxy]ethoxy]methyl]- 254746-76-4P 254746-82-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT **50-78-2**, **Aspirin** 52-01-7, Spironolactone 10238-21-8, Glyburide 51384-51-1, Metoprolol 55142-85-3, Ticlopidine 72956-09-3, Carvedilol 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 107724-20-9, Eplerenone 113665-84-2, Clopidogrel 134523-00-5, Atorvastatin 147098-20-2, Zd-4522 147526-32-7, NK 104 **150322-43-3**, **Cs-747**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT **50-78-2**, **Aspirin** **150322-43-3**, **Cs-747**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 50-78-2 HCAPLUS
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)




RN 150322-43-3 HCAPLUS
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



L25 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:504621 HCAPLUS
DN 137:52422
ED Entered STN: 05 Jul 2002
TI Medicinal compositions containing **aspirin**
IN **Asai, Fumitoshi; Sugidachi, Atsuhiro; Ogawa, Taketoshi; Inoue, Teruhiko**
PA **Sankyo Company, Limited, Japan; Ube Industries, Ltd.**
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K031-4365
ICS A61K031-616; A61P007-02
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002051412 | A1 | 20020704 | WO 2001-JP11201 | 20011220 <-- |
| W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| CA 2432644 | AA | 20020704 | CA 2001-2432644 | 20011220 <-- |
| JP 2002255814 | A2 | 20020911 | JP 2001-386850 | 20011220 <-- |
| EP 1350511 | A1 | 20031008 | EP 2001-271850 | 20011220 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | |
| BR 2001016531 | A | 20040225 | BR 2001-16531 | 20011220 <-- |
| NZ 526540 | A | 20041126 | NZ 2001-526540 | 20011220 <-- |
| US 2004024013 | A1 | 20040205 | US 2003-600266 | 20030620 <-- |
| ZA 2003004878 | A | 20040810 | ZA 2003-4878 | 20030623 <-- |
| NO 2003002902 | A | 20030624 | NO 2003-2902 | 20030624 <-- |
| PRAI JP 2000-392983 | A | 20001225 <-- | | |
| WO 2001-JP11201 | W | 20011220 <-- | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| WO 2002051412 | ICM | A61K031-4365 |
| | ICS | A61K031-616; A61P007-02 |
| WO 2002051412 | ECLA | A61K031/4365+M; A61K031/616+M; A61K045/06 <-- |
| EP 1350511 | ECLA | A61K031/4365+M; A61K031/616+M <-- |
| US 2004024013 | NCL | 514/301.000; 514/165.000 |
| | ECLA | A61K031/4365+M; A61K031/616+M; A61K045/06 <-- |

AB Disclosed are medicinal compns. containing as the active ingredients **2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4**

**,5,6,7-tetrahydrothieno[3**
**,2 c]pyridine** (I) or its pharmacol.
acceptable salt and **aspirin.** Because of having excellent
inhibitory effects on platelet aggregation and thrombosis, these compns.
are useful as preventives or remedies for diseases induced by thrombus or
embolization. A tablet was formulated containing I 10, **aspirin**
12.5, lactose 175.5, starch 50, and Mg stearate 2 mg.

ST platelet aggregation inhibitor tablet **aspirin**
thienopyridinylethanone deriv; anticoagulant tablet **aspirin**
thienopyridinylethanone deriv

IT Embolism
(embolization; medicinal compns. containing **aspirin** and
thienopyridinylethanone derivative)

IT Anticoagulants
Human
Platelet aggregation inhibitors
Thrombosis
(medicinal compns. containing **aspirin** and thienopyridinylethanone
derivative)

IT Drug delivery systems
(tablets; medicinal compns. containing **aspirin** and
thienopyridinylethanone derivative)

IT **50-78-2, Aspirin 150322-43-3**
**389574-19-0 389574-20-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(medicinal compns. containing **aspirin** and thienopyridinylethanone
derivative)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Asai, F; Annual Report of Sankyo Research Labolatories 1999, V51, P1
HCAPLUS
(2) Saniabadi, A; Cardiovascular Research 1991, V25(3), P177 HCAPLUS
(3) Sugidachi, A; British Journal of Pharmacology 2000, V209(7), P1439

IT **50-78-2, Aspirin 150322-43-3**
**389574-19-0 389574-20-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(medicinal compns. containing **aspirin** and thienopyridinylethanone
derivative)

RN 50-78-2 HCAPLUS
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)




RN 150322-43-3 HCAPLUS
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-
cyclopropyl-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 389574-19-0 HCAPLUS
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 389574-20-3 HCAPLUS
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150322-43-3
CMF C20 H20 F N O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L25 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:283949 HCAPLUS
DN 134:311218
ED Entered STN: 20 Apr 2001
TI Synthesis and use of heterocyclic sodium/proton exchange inhibitors
IN Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D405-08
ICS C07D413-08; C07D233-88; C07D233-54; C07D239-48; C07D417-08; C07D277-20; C07D401-04; C07D417-04; C07D409-04; C07D403-08; C07D401-14; C07D409-14; C07D403-04; C07D403-06; C07D487-04; C07D471-04; C07D417-14; C07D513-04; C07D405-14
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2001027107 | A2 | 20010419 | WO 2000-US27461 | 20001002 <-- |
| | WO 2001027107 | A3 | 20020124 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6887870 | B1 | 20050503 | US 2000-669298 | 20000925 <-- |
| | CA 2388813 | AA | 20010419 | CA 2000-2388813 | 20001002 <-- |
| | EP 1224183 | A2 | 20020724 | EP 2000-968723 | 20001002 <-- |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | BR 2000014725 | A | 20030617 | BR 2000-14725 | 20001002 <-- |
| | JP 2003527331 | T2 | 20030916 | JP 2001-530325 | 20001002 <-- |
| | NZ 517668 | A | 20040924 | NZ 2000-517668 | 20001002 <-- |
| | ZA 2002002479 | A | 20040727 | ZA 2002-2479 | 20020327 <-- |
| | NO 2002001717 | A | 20020610 | NO 2002-1717 | 20020411 <-- |
| | US 2005137216 | A1 | 20050623 | US 2005-46993 | 20050131 <-- |
| PRAI | US 1999-158755P | P | 19991012 <-- | | |
| | US 2000-669298 | A3 | 20000925 <-- | | |
| | WO 2000-US27461 | W | 20001002 <-- | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| WO 2001027107 | ICM | C07D405-08 |
| | ICS | C07D413-08; C07D233-88; C07D233-54; C07D239-48; |

C07D417-08; C07D277-20; C07D401-04; C07D417-04;
C07D409-04; C07D403-08; C07D401-14; C07D409-14;
C07D403-04; C07D403-06; C07D487-04; C07D471-04;
C07D417-14; C07D513-04; C07D405-14

WO 2001027107 ECLA C07D233/54C2B; C07D233/54C2D1; C07D233/88;
C07D239/48B5A; C07D277/20D; C07D277/40;
C07D401/04+233+213; C07D401/14+233+213+211;
C07D401/14+239B+233+211; C07D401/14+237B+233+211;
C07D401/14+233+231+211; C07D401/14+257+233+211;
C07D403/08+249B+233; C07D405/08+307+233;
C07D405/08+307+249B; C07D409/14+333B+233+211;
C07D417/08+307+277B; C07D471/04+235C+221C;
C07D487/04+239C+235 <--

US 6887870 NCL 514/235.800; 514/241.000; 514/242.000; 514/250.000;
514/253.090; 514/253.100; 514/256.000; 514/259.410;
514/260.100; 514/300.000 <--

US 2005137216 NCL 514/269.000; 514/275.000; 514/326.000; 514/300.000;
514/399.000; 544/329.000; 546/118.000; 546/210.000;
514/383.000; 546/211.000 <--

OS MARPAT 134:311218

GI




AB Compds. of formula I [wherein; n is 1-5; X is N or CR5, where R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R1 is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R2, R3 and R4 are any of the groups set out for R1 and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R1 is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butyldiethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding α-chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents, β-adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

ST imidazole benzofuran prepn cyclopropane antianginal cardioprotective; pyrazole thiazole triazole tetrazole pyridine piperidine pyrimidine antianginal cardioprotective; sodium proton exchange inhibitor imidazole benzofuran cyclopropane pyrazole thiazole

IT 5-HT antagonists
(5-HT2A, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Lipoprotein receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LDL, upregulator of, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MTP (microsomal triglyceride-exchanging protein), inhibitor of, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Blood vessel, disease
(Raynaud's phenomenon, treatment of; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Phosphoproteins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aP2 (adipocyte protein 2), inhibitor, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Peroxisome proliferator-activated receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Heart, disease
(angina pectoris, treating disorders caused by intracellular acidosis during; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Angiotensin receptor antagonists
(angiotensin II, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Fibrinogen receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonist, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Heart, disease
(arrhythmia, treating disorders caused by intracellular acidosis during; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Ion channel blockers
(calcium, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Cytoprotective agents
(cardioprotective; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Anti-inflammatory agents
(corticosteroids, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Heart, disease
(failure, treating disorders caused by intracellular acidosis during; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT Transport proteins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogen ion-sodium-exchanging, inhibitors of; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Heart, disease
(infarction, treating disorders caused by intracellular acidosis during; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Appetite depressants
(inhibitor, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Reperfusion
(injury, treating disorders caused by intracellular acidosis during; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Artery, disease
(intermittent claudication, prevention/treatment of; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Acidosis
(intracellular; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Heart, disease
(ischemia, treating disorders caused by intracellular acidosis during; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Pain
(lower limb and gluteal regions, relief of; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Atherosclerosis
Blood vessel, disease
(peripheral, treatment of; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Adrenoceptor agonists
Antiarrhythmics
Antidiabetic agents
Antihypertensives
Antiobesity agents
Cholinergic antagonists
Hypolipemic agents
Platelet aggregation inhibitors
Thromboxane receptor antagonists
(pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Sulfonylureas
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Antianginal agents
(synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Osteoporosis
(therapeutic agents, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Heart, disease
Hypertension
Kidney, disease
(treating disorders caused by intracellular acidosis during; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT Ischemia

(treatment of; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT Thyroid hormone receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT Adrenoceptor agonists
Adrenoceptor antagonists
(β-, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 105913-11-9, Plasminogen activator
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complex, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 9025-82-5, Phosphodiesterase 9029-60-1, Lipoxygenase 9077-14-9, Squalene synthetase 60832-04-4, TXA2 synthetase 138757-15-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor of, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 54249-88-6, Dipeptidyl peptidase iv 335197-46-1, SGLT 2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor, pharmaceuticals also containing)

IT 9001-62-1, Lipase 9027-63-8, Acat 9033-06-1, Glucosidase 96829-58-2, Orlistat 282526-98-1, ATL 962
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 35121-78-9, Prostacyclin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mimetic, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 9004-10-8, Insulin, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(or sensitizers, pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 50-02-2, Dexamethasone **50-78-2**, **Aspirin** 51-64-9, Dexamphetamine 52-53-9, Verapamil 56-03-1, Biguanide 58-32-2, Dipyridamole 58-55-9, Theophylline, biological studies 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 124-94-7, Triamcinolone 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 943-45-3D, Fibric acid, derivs. 3385-03-3, Flunisolide 4205-91-8, Clonidine hydrochloride 4419-39-0, Beclomethasone 9002-01-1, Streptokinase 9015-82-1, ACE 9039-53-6, Urokinase 10238-21-8, Glyburide 13392-18-2, Fenoterol 14838-15-4, Phenylpropanolamine 16110-51-3, Cromolyn 18559-94-9, Albuterol 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4,

Nifedipine 22232-71-9, Mazindol 23031-25-6, Terbutaline 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 30392-40-6, Bitolterol 37250-24-1, HMG CoA reductase 38677-81-5, Pirbuterol 42200-33-9, Nadolol 49562-28-9, Fenofibrate 51333-22-3, Budesonide 54870-28-9, Meglitinide 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 69049-73-6, Nedocromil 72432-03-2, Miglitol 72956-09-3, Carvedilol 73573-87-2, Formoterol 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 89365-50-4, Salmeterol 89750-14-1, Glucagon-like peptide I 90566-53-3, Fluticasone 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 103177-37-3, Pranlukast 103775-10-6, Moexipril 105816-04-4, Nateglinide 105857-23-6, Activase 106650-56-0, Sibutramine 107753-78-6, Zafirlukast 111025-46-8, Pioglitazone 111406-87-2, Zileuton 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 133652-38-7, Reteplase 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 139639-23-9, Tissue plasminogen activator 141758-74-9, AC 2993 143443-90-7, Ifetroban 144288-97-1, TS 962 145599-86-6, Cerivastatin 147511-69-1, Itavastatin **150322-43-3**, **CS 747** 152755-31-2, LY295427 158966-92-8, Montelukast 159183-92-3, L750355 160135-92-2 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, CGS-30440 170861-63-9, JTT-501 171870-23-8, Lanoteplase 176435-10-2, LY315902 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4, GI-262570 199113-98-9, NN 2344 199914-96-0 213252-19-8, KRP297 244081-42-3, AJ9677 251572-86-8 335149-05-8, AZ 4522 335149-08-1, L 895645 335149-14-9, R 119702 335149-15-0, KAD 1129 335149-17-2, ARHO 39242 335149-19-4, GW 409544 335149-23-0, NVP-DPP 728A 335149-25-2, CP 331648

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 335060-69-0P 335060-71-4P 335060-77-0P 335060-79-2P 335060-83-8P 335060-87-2P 335060-91-8P 335060-94-1P 335060-95-2P 335061-95-5P 335061-96-6P 335062-12-9P 335062-43-6P 335062-57-2P 335063-76-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 146365-55-1P 335060-70-3P 335060-72-5P 335060-73-6P 335060-74-7P 335060-75-8P 335060-76-9P 335060-78-1P 335060-80-5P 335060-81-6P 335060-82-7P 335060-84-9P 335060-85-0P 335060-86-1P 335060-88-3P 335060-89-4P 335060-90-7P 335060-92-9P 335060-93-0P 335060-96-3P 335060-97-4P 335060-98-5P 335060-99-6P 335061-00-2P 335061-01-3P 335061-02-4P 335061-03-5P 335061-04-6P 335061-05-7P 335061-06-8P 335061-08-0P 335061-09-1P 335061-10-4P 335061-11-5P 335061-12-6P 335061-13-7P 335061-14-8P 335061-15-9P 335061-16-0P 335061-17-1P 335061-18-2P 335061-19-3P 335061-20-6P 335061-21-7P 335061-22-8P 335061-23-9P 335061-24-0P 335061-25-1P 335061-26-2P 335061-27-3P 335061-28-4P 335061-29-5P 335061-30-8P 335061-31-9P 335061-32-0P 335061-33-1P 335061-34-2P 335061-35-3P 335061-36-4P 335061-37-5P 335061-38-6P 335061-39-7P 335061-40-0P 335061-41-1P 335061-42-2P 335061-43-3P 335061-44-4P 335061-45-5P 335061-46-6P 335061-47-7P 335061-48-8P 335061-49-9P 335061-50-2P 335061-51-3P 335061-52-4P 335061-53-5P 335061-54-6P 335061-55-7P 335061-56-8P 335061-57-9P

335061-58-0P 335061-59-1P 335061-60-4P 335061-61-5P 335061-62-6P
335061-63-7P 335061-64-8P 335061-65-9P 335061-66-0P 335061-67-1P
335061-68-2P 335061-69-3P 335061-70-6P 335061-71-7P 335061-72-8P
335061-73-9P 335061-74-0P 335061-75-1P 335061-76-2P 335061-77-3P
335061-78-4P 335061-79-5P 335061-83-1P 335061-84-2P 335061-86-4P
335061-88-6P 335061-90-0P 335061-92-2P 335061-93-3P 335061-94-4P
335061-97-7P 335061-98-8P 335061-99-9P 335062-00-5P 335062-01-6P
335062-02-7P 335062-03-8P 335062-04-9P 335062-05-0P 335062-06-1P
335062-07-2P 335062-08-3P 335062-09-4P 335062-10-7P 335062-11-8P
335062-13-0P 335062-15-2P 335062-16-3P 335062-17-4P 335062-18-5P
335062-19-6P 335062-20-9P 335062-21-0P 335062-22-1P 335062-23-2P
335062-24-3P 335062-25-4P 335062-26-5P 335062-27-6P 335062-28-7P
335062-29-8P 335062-30-1P 335062-31-2P 335062-32-3P 335062-33-4P
335062-34-5P 335062-35-6P 335062-36-7P 335062-37-8P 335062-38-9P
335062-39-0P 335062-40-3P 335062-41-4P 335062-42-5P 335062-44-7P
335062-45-8P 335062-46-9P 335062-47-0P 335062-48-1P 335062-49-2P
335062-50-5P 335062-51-6P 335062-52-7P 335062-53-8P 335062-54-9P
335062-55-0P 335062-56-1P 335062-58-3P 335062-59-4P 335062-60-7P
335062-61-8P 335062-62-9P 335062-63-0P 335062-64-1P 335062-65-2P
335062-66-3P 335062-67-4P 335062-68-5P 335062-69-6P 335062-71-0P
335062-72-1P 335062-73-2P 335062-74-3P 335062-75-4P 335062-76-5P
335062-77-6P 335062-78-7P 335062-79-8P 335062-80-1P 335062-81-2P
335062-82-3P 335062-83-4P 335062-84-5P 335062-85-6P 335062-86-7P
335062-87-8P 335062-88-9P 335062-89-0P 335062-90-3P 335062-91-4P
335062-92-5P 335062-93-6P 335062-94-7P 335062-95-8P 335062-96-9P
335062-97-0P 335062-98-1P 335062-99-2P 335063-00-8P 335063-01-9P
335063-02-0P 335063-03-1P 335063-04-2P 335063-05-3P 335063-06-4P
335063-07-5P 335063-08-6P 335063-09-7P 335063-10-0P 335063-11-1P
335063-12-2P 335063-13-3P 335063-14-4P 335063-15-5P 335063-16-6P
335063-17-7P 335063-18-8P 335063-19-9P 335063-20-2P 335063-21-3P
335063-22-4P 335063-23-5P 335063-24-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 335063-25-7P 335063-26-8P 335063-27-9P 335063-28-0P 335063-29-1P
335063-30-4P 335063-31-5P 335063-32-6P 335063-33-7P 335063-34-8P
335063-35-9P 335063-36-0P 335063-37-1P 335063-38-2P 335063-39-3P
335063-40-6P 335063-41-7P 335063-42-8P 335063-43-9P 335063-44-0P
335063-45-1P 335063-46-2P 335063-47-3P 335063-48-4P 335063-49-5P
335063-50-8P 335063-51-9P 335063-52-0P 335063-53-1P 335063-54-2P
335063-55-3P 335063-56-4P 335063-57-5P 335063-58-6P 335063-59-7P
335063-61-1P 335063-62-2P 335063-63-3P 335063-64-4P 335063-65-5P
335063-66-6P 335063-67-7P 335063-68-8P 335063-69-9P 335063-70-2P
335063-71-3P 335063-72-4P 335063-73-5P 335063-74-6P 335063-75-7P
335063-77-9P 335063-78-0P 335063-79-1P 335063-80-4P 335063-81-5P
335063-82-6P 335063-83-7P 335063-84-8P 335063-85-9P 335063-86-0P
335063-87-1P 335063-88-2P 335063-89-3P 335063-90-6P 335063-91-7P
335063-92-8P 335063-93-9P 335063-94-0P 335063-95-1P 335063-96-2P
335063-97-3P 335063-98-4P 335063-99-5P 335064-00-1P 335064-01-2P
335064-02-3P 335064-03-4P 335064-04-5P 335064-05-6P 335064-06-7P
335064-07-8P 335064-08-9P 335064-09-0P 335064-10-3P 335064-11-4P
335064-12-5P 335064-13-6P 335064-14-7P 335064-15-8P 335064-16-9P
335064-17-0P 335064-18-1P 335064-19-2P 335064-20-5P 335064-21-6P
335064-22-7P 335064-23-8P 335064-24-9P 335064-25-0P 335064-26-1P
335064-27-2P 335064-28-3P 335064-29-4P 335064-30-7P 335064-31-8P
335064-32-9P 335064-33-0P 335064-34-1P 335064-35-2P 335064-37-4P
335064-39-6P 335064-40-9P 335064-41-0P 335064-42-1P 335064-43-2P
335064-44-3P 335064-45-4P 335064-98-7P 335064-99-8P 335065-00-4P
335065-01-5P 335065-02-6P 335065-03-7P 335065-04-8P 335065-05-9P

335065-06-0P 335065-07-1P 335065-08-2P 335065-09-3P 335065-10-6P
335065-11-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 50-01-1, Guanidine hydrochloride 62-56-6, Thiourea, reactions 75-12-7, Formamide, reactions 79-30-1, Isobutyryl chloride 103-71-9, Phenylisocyanate, reactions 107-12-0, Propionitrile 107-97-1, Sarcosine 141-75-3, Butyryl chloride 143-37-3, Acetamidine 288-88-0, 1H-1,2,4-Triazole 289-95-2, Pyrimidine 302-01-2, Hydrazine, reactions 393-52-2, 2-Fluorobenzoyl chloride 459-64-3, 4-Methoxybenzenediazonium tetrafluoroborate 498-94-2, Isonipecotic acid 504-29-0, 2-Aminopyridine 542-92-7, Cyclopentadiene, reactions 623-73-4, Ethyl diazoacetate 626-05-1, 2,6-Dibromopyridine 645-49-8, cis-Stilbene 925-90-6, Ethyl magnesium bromide 953-26-4, Ethyl 4-nitrocinnamate 1116-98-9, tert-Butyl cyanoacetate 2106-50-5, 3-Chloro-4-nitrofluorobenzene 2208-08-4, Ethyl butanimidate hydrochloride 2260-00-6 2459-05-4, Fumaric acid monoethyl ester 2582-30-1, Aminoguanidine bicarbonate 2812-46-6 5470-18-8, 2-Chloro-3-nitropyridine 5699-40-1, Acetyl guanidine 10203-08-4, 3,5-Dichlorobenzaldehyde 10255-95-5, 2-Phenylmalonamide 13115-21-4, Hydroxy guanidine 14210-25-4 14473-90-6 14763-20-3, 3-Chlorophenylhydrazine 15677-02-8, Carboxymethylene triphenylphosphorane 15795-20-7, Ethyl 4-Bromocinnamate 18908-07-1, 3-Methoxyphenylisocyanate 23255-20-1, 3-Pyridinecarboximidamide 24470-78-8, Isopropyltriphenylphosphonium iodide 27784-76-5, tert-Butyldiethylphosphonoacetate 28539-02-8, 1H-Benzotriazole-1-methanol 36082-50-5, 5-Bromo-2,4-dichloropyrimidine 55440-54-5, 5-Chloro-2-methoxyphenylisocyanate 63558-65-6, 4-Chloro-5-iodopyrimidine 144432-85-9, 3-Chloro-4-fluorophenyl boronic acid 147960-33-6 155511-82-3 230642-84-9 230642-86-1 312490-78-1 335065-12-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 3974-16-1P 4605-54-3P 18337-64-9P 64200-25-5P 100922-16-5P 209256-42-8P 209256-90-6P 230642-77-0P 230642-78-1P 230642-79-2P 230642-97-4P 230642-98-5P 230642-99-6P 230643-04-6P 335064-46-5P 335064-47-6P 335064-48-7P 335064-49-8P 335064-50-1P 335064-51-2P 335064-52-3P 335064-53-4P 335064-54-5P 335064-55-6P 335064-56-7P 335064-57-8P 335064-58-9P 335064-59-0P 335064-60-3P 335064-61-4P 335064-62-5P 335064-63-6P 335064-64-7P 335064-65-8P 335064-66-9P 335064-67-0P 335064-68-1P 335064-69-2P 335064-70-5P 335064-71-6P 335064-72-7P 335064-73-8P 335064-74-9P 335064-75-0P 335064-76-1P 335064-77-2P 335064-78-3P 335064-79-4P 335064-80-7P 335064-81-8P 335064-82-9P 335064-83-0P 335064-84-1P 335064-85-2P 335064-86-3P 335064-87-4P 335064-88-5P 335064-89-6P 335064-90-9P 335064-91-0P 335064-92-1P 335064-93-2P 335064-94-3P 335064-95-4P 335064-96-5P 335064-97-6P 335065-13-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT **50-78-2, Aspirin 150322-43-3, CS 747**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

RN 50-78-2 HCAPLUS
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)




RN 150322-43-3 HCAPLUS
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




=> fil wpix
FILE 'WPIX' ENTERED AT 06:42:36 ON 05 JUL 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 4 JUL 2005 <20050704/UP>
MOST RECENT DERWENT UPDATE: 200542 <200542/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://thomsonderwent.com/coverage/latestupdates/ <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT:
http://thomsonderwent.com/support/userguides/ <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/
FOR DETAILS. <<<

=> => d l51 all abeq tech abex tot

L51 ANSWER 1 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN **2004-821596** [81] WPIX
DNC **C2004-285648**
TI Treatment or prevention of cardiovascular diseases involves administering

**2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-flurorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine**, and performing percutaneous coronary intervention procedure.

DC B02
IN BRANDT, J T; FARID, N A; JAKUBOWSKI, J A; WINTERS, K J
PA (ELIL) LILLY & CO ELI
CYC 108
PI WO 2004098713 A2 20041118 (200481)* EN 31 A61P009-00
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
ADT WO 2004098713 A2 WO 2004-US11257 20040426
PRAI US 2003-467903P 20030505
IC ICM A61P009-00
ICS A61K031-4365; A61K031-60
AB WO2004098713 A UPAB: 20041216
NOVELTY - Treatment or prevention of cardiovascular diseases and their recurrence involves administration of **2-acetoxy-5-( alpha -cyclopropylcarbonyl-2-flurorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine** (I) optionally in combination with **aspirin**; performing a percutaneous coronary intervention (PCI) procedure; and optionally administering (I) optionally in combination with **aspirin.**

DETAILED DESCRIPTION - Treatment or prevention of cardiovascular diseases and their recurrence involves administration of **2-acetoxy-5-( alpha -cyclopropylcarbonyl-2-flurorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine** (I), its salt, solvate, active metabolite, prodrug, racemate or enantiomer, optionally in combination with **aspirin**; performing a percutaneous coronary intervention (PCI) procedure; and optionally administering (I) optionally in combination with **aspirin.**

INDEPENDENT CLAIMS are included for the following:

(1) a device coated or impregnated with (I);

(2) use of (I) in conjunction with a stent for treating or preventing recurrence of peripheral vascular disease and cerebrovascular disease; and

(3) treatment and prevention of cardiovascular disease and its recurrence involving administering (I), in combination with a stent impregnated with (I) and/or other cardio-protective agent.

ACTIVITY - Cardiovascular-Gen.; Vasotropic; Cardiant; Antiinflammatory; Antiarrhythmic.

MECHANISM OF ACTION - None given.

USE - In the manufacture of a medicament for treating or preventing the recurrence of cardiovascular disease e.g. coronary occlusion, restenosis, acute coronary syndrome, high risk vascular diseases, congestive heart failure, cardiac alternation, ventricular aneurysm, mural aneurysm, myocardial infarction, cardiac arrest, cardiac dysrhythmia including atrial fibrillation, cardiac edema, cardiac dyspnea, cardiac failure, tachycardia, cardiac hemoptysis, cardiac incompetence, cardiac murmur, cardiac syncope, cardiac tamponade, cerebrovascular disease and peripheral artery disease (claimed).

ADVANTAGE - The method improves or augments the efficiency of interventional procedures including stenting and balloon angioplasty to minimize recurrences and repeated interventions.
Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B06-F03; B10-C04B
TECH UPTX: 20041216
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: (m1) involves administration of (I), optionally in combination with **aspirin** or other cardio protective agent to 2 - 30 days prior to performing the PCI procedure; performing PCI procedure; and administering (I) optionally in combination with **aspirin** or other cardio protective agent to 0 - 365 days after performance of the PCI procedure.
ABEX UPTX: 20041216
SPECIFIC COMPOUNDS - Use of **2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-flurorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine** hydrochloride addition salt is specifically claimed.

ADMINISTRATION - The dosage of (I) is 0.01 - 50 mg/kg.

EXAMPLE - No relevant example given.

L51 ANSWER 2 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN **2002-537764** [57] WPIX
DNC **C2002-152533**
TI Composition for treating and preventing diseases in which thrombosis or embolism is a factor e.g. cerebral ischemia comprises tetrahydrothieno(3,2-c)pyridine compound and **aspirin**..
DC B02
IN ASAI, F; INOUE, T; OGAWA, T; SUGIDACHI, A
PA (SANY) SANKYO CO LTD; (UBEI) UBE IND LTD
CYC 43

| | | | | | | |
|---|---|---|---|---|---|---|
| PI | WO 2002051412 | A1 | 20020704 (200257)* | JA | 17 | A61K031-4365 |
| | RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR | | | | | |
| | W: AU BR CA CN CO CZ HU ID IL IN KR MX NO NZ PH PL RU SG SK US VN ZA | | | | | |
| | JP 2002255814 | A | 20020911 (200275) | | 5 | A61K031-4365 |
| | NO 2003002902 | A | 20030624 (200361) | | | A61K000-00 |
| | EP 1350511 | A1 | 20031008 (200370) | EN | | A61K031-4365 |
| | R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR | | | | | |
| | KR 2003065558 | A | 20030806 (200402) | | | A61K031-616 |
| | CZ 2003001660 | A3 | 20031217 (200404) | | | A61K031-4365 |
| | SK 2003000754 | A3 | 20031201 (200404) | | | A61K031-4365 |
| | US 2004024013 | A1 | 20040205 (200411) | | | A61K031-60 |
| | BR 2001016531 | A | 20040225 (200416) | | | A61K031-4365 |
| | AU 2002217464 | A1 | 20020708 (200427) | | | A61K031-4365 |
| | CN 1491109 | A | 20040421 (200446) | | | A61K031-4365 |
| | HU 2004000644 | A2 | 20040628 (200452) | | | A61K031-4365 |
| | MX 2003005770 | A1 | 20031001 (200466) | | | A61K031-4365 |
| | ZA 2003004878 | A | 20041027 (200474) | | 25 | A61K000-00 |
| | NZ 526540 | A | 20041126 (200479) | | | A61K031-33 |
| | AU 2002217464 | B2 | 20041216 (200508) | | | A61K031-4365 |
| | IN 2003000777 | P2 | 20041204 (200530) | EN | | A61K000-00 |

ADT WO 2002051412 A1 WO 2001-JP11201 20011220; JP 2002255814 A JP 2001-386850 20011220; NO 2003002902 A WO 2001-JP11201 20011220, NO 2003-2902 20030624; EP 1350511 A1 EP 2001-271850 20011220, WO 2001-JP11201 20011220; KR 2003065558 A KR 2003-708323 20030620; CZ 2003001660 A3 WO 2001-JP11201 20011220, CZ 2003-1660 20011220; SK 2003000754 A3 WO 2001-JP11201

20011220, SK 2003-754 20011220; US 2004024013 A1 Cont of WO 2001-JP11201 20011220, US 2003-600266 20030620; BR 2001016531 A BR 2001-16531 20011220, WO 2001-JP11201 20011220; AU 2002217464 A1 AU 2002-217464 20011220; CN 1491109 A CN 2001-822768 20011220; HU 2004000644 A2 WO 2001-JP11201 20011220, HU 2004-644 20011220; MX 2003005770 A1 WO 2001-JP11201 20011220, MX 2003-5770 20030624; ZA 2003004878 A ZA 2003-4878 20030623; NZ 526540 A NZ 2001-526540 20011220, WO 2001-JP11201 20011220; AU 2002217464 B2 AU 2002-217464 20011220; IN 2003000777 P2 WO 2001-JP11201 20011220, IN 2003-KN777 20030613

FDT EP 1350511 A1 Based on WO 2002051412; CZ 2003001660 A3 Based on WO 2002051412; SK 2003000754 A3 Based on WO 2002051412; BR 2001016531 A Based on WO 2002051412; AU 2002217464 A1 Based on WO 2002051412; HU 2004000644 A2 Based on WO 2002051412; MX 2003005770 A1 Based on WO 2002051412; NZ 526540 A Based on WO 2002051412; AU 2002217464 B2 Previous Publ. AU 2002217464, Based on WO 2002051412

PRAI JP 2000-392983 20001225

IC ICM A61K000-00; A61K031-33; A61K031-4365; A61K031-60; A61K031-616
ICS A61K031-435; A61K031-4743; A61P007-00; A61P007-02; A61P009-00; A61P009-10; A61P043-00

AB WO 200251412 A UPAB: 20020906
NOVELTY - Composition comprises **2-acetoxy-5-( alpha -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c) pyridine** (I) and **aspirin.**

DETAILED DESCRIPTION - Composition comprises **2-acetoxy-5-( alpha -cyclopropylcarbonyl -2-fluorobenzyl)-4,5,6, 7-tetrahydrothieno(3,2-c) pyridine** of formula (I) or its salt and **aspirin.**

ACTIVITY - Antiaggregant; Anticoagulant; Thrombolytic; Antianginal; Cerebroprotective; Vasotropic; Antiarteriosclerotic; Antidiabetic.

In vascular stent thrombosis model in Sprague Dawley rats oral administration of **2-acetoxy-5-( alpha -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c) pyridine** (I) at 0.3 mg/kg and **aspirin** at 10 mg/kg reduced thrombus weight by 41.8% compared to a control. The corresponding values for (I) at 0.3 mg/kg and **aspirin** at 10 mg/kg were 17.0% and 12.3% respectively.

MECHANISM OF ACTION - None given.

USE - As platelet aggregation inhibitors for treating and preventing diseases in which thrombosis or embolism is a factor such as unstable angina, cerebral ischemia, restenosis after arterial stent removal or cardiac bypass surgery, atherosclerosis, diabetic thromboembolic disorders and peripheral vascular disorders,

ADVANTAGE - Combination is synergistic.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B06-F03; B10-C03; B14-F01D; B14-F01E; B14-F02D; B14-F07

TECH UPTX: 20020906
TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Active Agent: (I) is preferably in its maleic acid or hydrochloric acid salt.

ABEX UPTX: 20020906
ADMINISTRATION - Dosage is 0.1-1000 (preferably 1-500) mg/day orally or 0.01-500 (preferably 0.1-250) mg/day intravenously using a ratio of (I): **aspirin** of 1:500-500:1.

```
=> => fil uspatfull
FILE 'USPATFULL' ENTERED AT 06:44:24 ON 05 JUL 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 5 Jul 2005 (20050705/PD)
FILE LAST UPDATED: 5 Jul 2005 (20050705/ED)
HIGHEST GRANTED PATENT NUMBER: US6915531
HIGHEST APPLICATION PUBLICATION NUMBER: US2005144692
CA INDEXING IS CURRENT THROUGH 5 Jul 2005 (20050705/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 5 Jul 2005 (20050705/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2005

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together        <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d l28 bib abs kwic hitstr tot

L28  ANSWER 1 OF 37  USPATFULL on STN
AN     2005:159006  USPATFULL
TI     Heterocyclic sodium/proton exchange inhibitors and method
IN     Ahmad, Saleem, Wall, NJ, UNITED STATES
       Wu, Shung C., Princeton, NJ, UNITED STATES
       O'Neil, Steven V., Newtown, PA, UNITED STATES
       Ngu, Khehyong, Pennington, NJ, UNITED STATES
       Atwal, Karnail S., Newtown, PA, UNITED STATES
       Weinstein, David S., East Windsor, NJ, UNITED STATES
PI     US 2005137216      A1   20050623
AI     US 2005-46993      A1   20050131 (11)
RLI    Division of Ser. No. US 2000-669298, filed on 25 Sep 2000, GRANTED, Pat.
       No. US 6887870
PRAI   US 1999-158755P     19991012 (60)                                <--
DT     Utility
FS     APPLICATION
LREP   STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
       BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN   Number of Claims: 62
ECL    Exemplary Claim: 1
DRWN   No Drawings
```

LN.CNT 3409
AB Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure ##STR1## wherein n is 1 to 5; X is N or C--R.sup.5 wherein R.sup.5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and where X is N, R.sup.1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

PRAI US 1999-158755P 19991012 (60) <--
DETD . . . in combination with one or more anti-platelet agents or platelet aggregation inhibitors or P2Y(AC) antagonists such as clopidogrel, ticlopidine and **CS-747**, one or more GPIIb/IIIa blockers such as abciximab (Reopro®), eptifibatide (Integrilin®), and tirofiban (Aggrastat), eptifibalide, anagrelide, one or more thromboxane. . .
DETD . . . melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (niacin), acipimox, acifran, neomycin, p-aminosalicylic acid, **aspirin**, poly(diallylmethylamine) derivatives such as disclosed in U.S. Pat. No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in. . .
CLM What is claimed is:
. . . antagonist, a prostacyclin mimetic, a phosphodiesterase (PDE) inhibitor, a thromboxane A synthetase inhibitor, a serotonin-2-receitor antagonist, a fibrinogen receptor antagonist, **aspirin**, a hypolipidemic agent, an antidiabetic agent, an antihypertensive agent, a β-adrenergic agonist, an anticholinergic agent, an anti-inflammatory cortiocosteroid or an. . .
46. The pharmaceutical combination as defined in claim 44 wherein the platelet aggregation inhibitor is clopidogrel, ticolopidine, or **CS-747**, or ifetroban or **aspirin**, the antihypertensive agent is omapatrilat, gemopatrilat, lisinopril, fosinopril, irbesartan, losartan, valsartan, carvedilol, amlodipine besylate, the β-adrenergic agonist is albuterol, terbutaline,. .
.
62. The combination as defined in claim 50 wherein the platelet aggregation inhibitor is **aspirin**, clopidogrel, ticlopidine, dipyridamole or ifetroban.

L28 ANSWER 2 OF 37 USPATFULL on STN
AN 2005:138578 USPATFULL
TI METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Mitt, Toomas, Plainsboro, NJ, UNITED STATES
Patel, Ramesh N., Bridgewater, NJ, UNITED STATES
Hanson, Ronald L., Morris Plains, NJ, UNITED STATES
Brzozowski, David, Piscataway, NJ, UNITED STATES
Goswami, Animesh, Plainsboro, NJ, UNITED STATES
Chu, Linda Nga Hoong, East Brunswick, NJ, UNITED STATES
Li, Wen-sen, Holmdel, NJ, UNITED STATES
Simpson, James H., Hillsborough, NJ, UNITED STATES
Totleben, Michael J., North Brunswick, NJ, UNITED STATES
He, Weixuan, Dayton, NJ, UNITED STATES
PI US 2005119228 A1 20050602

AI US 2001-24878 A1 20011219 (10) <--
RLI Continuation-in-part of Ser. No. US 2001-885381, filed on 20 Jun 2001, PENDING
PRAI US 2000-233519P 20000919 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12860
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

AI US 2001-24878 A1 20011219 (10) <--
PRAI US 2000-233519P 20000919 (60) <--
DETD . . . the compounds of the present invention include prednisone, dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®) integrin antagonists, alpha-4. . .
DETD . . . combination with the compounds of the present invention include GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**), thromboxane receptor antagonists (e.g., ifetroban), **aspirin**, and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin**.

L28 ANSWER 3 OF 37 USPATFULL on STN
AN 2005:107307 USPATFULL
TI Heterocyclic sodium/proton exchange inhibitors and method
IN Ahmad, Saleem, Wall, NJ, UNITED STATES
Wu, Shung C., Princeton, NJ, UNITED STATES
O'Neil, Steven V., Newtown, PA, UNITED STATES
Ngu, Khehyong, Pennington, NJ, UNITED STATES
Atwal, Karnail S., Newtown, PA, UNITED STATES
Weinstein, David S., East Windsor, NJ, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 6887870 B1 20050503
AI US 2000-669298 20000925 (9) <--
PRAI US 1999-158755P 19991012 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.
LREP Rodney, Burton
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3386
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure ##STR1## wherein n is 1 to 5; X is N or C--R.sup.5 wherein R.sup.5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R.sup.1, R.sup.2,

R.sup.3 and R.sup.4 are as defined herein, and where X is N. R.sup.1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2000-669298 20000925 (9) <--
PRAI US 1999-158755P 19991012 (60) <--
DETD . . . in combination with one or more anti-platelet agents or platelet aggregation inhibitors or P2Y(AC) antagonists such as clopidogrel, ticlopidine and **CS-747**, one or more GPIIb/IIIa blockers such as abciximab (Reopro®), eptifibatide (Integrilin®), and tirofiban (Aggrastat), eptifibalide, anagrelide, one or more thromboxane. . .
DETD . . . melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (niacin), acipimox, acifran, neomycin, p-aminosalicylic acid, **aspirin**, poly(diallylmethylamine) derivatives such as disclosed in U.S. Pat. No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in. . .
IT 50-02-2, Dexamethasone **50-78-2**, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 56-03-1, Biguanide 58-32-2, Dipyridamole 58-55-9, Theophylline, biological studies 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 124-94-7, Triamcinolone 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 943-45-3D, Fibric acid, derivs. 3385-03-3, Flunisolide 4205-91-8, Clonidine hydrochloride 4419-39-0, Beclomethasone 9002-01-1, Streptokinase 9015-82-1, ACE 9039-53-6, Urokinase 10238-21-8, Glyburide 13392-18-2, Fenoterol 14838-15-4, Phenylpropanolamine 16110-51-3, Cromolyn 18559-94-9, Albuterol 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 23031-25-6, Terbutaline 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 30392-40-6, Bitolterol 37250-24-1, HMG CoA reductase 38677-81-5, Pirbuterol 42200-33-9, Nadolol 49562-28-9, Fenofibrate 51333-22-3, Budesonide 54870-28-9, Meglitinide 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 69049-73-6, Nedocromil 72432-03-2, Miglitol 72956-09-3, Carvedilol 73573-87-2, Formoterol 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 89365-50-4, Salmeterol 89750-14-1, Glucagon-like peptide I 90566-53-3, Fluticasone 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 103177-37-3, Pranlukast 103775-10-6, Moexipril 105816-04-4, Nateglinide 105857-23-6, Activase 106650-56-0, Sibutramine 107753-78-6, Zafirlukast 111025-46-8, Pioglitazone 111406-87-2, Zileuton 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 133652-38-7, Reteplase 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 139639-23-9, Tissue plasminogen activator 141758-74-9, AC 2993 143443-90-7, Ifetroban 144288-97-1, TS 962 145599-86-6, Cerivastatin 147511-69-1, Itavastatin **150322-43-3**, CS 747 152755-31-2, LY295427 158966-92-8, Montelukast 159183-92-3, L750355 160135-92-2 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, CGS-30440 170861-63-9, JTT-501 171870-23-8, Lanoteplase 176435-10-2, LY315902 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4, GI-262570 199113-98-9, NN 2344 199914-96-0

213252-19-8, KRP297 244081-42-3, AJ9677 251572-86-8 335149-05-8, AZ 4522 335149-08-1, L 895645 335149-14-9, R 119702 335149-15-0, KAD 1129 335149-17-2, ARHO 39242 335149-19-4, GW 409544 335149-23-0, NVP-DPP 728A 335149-25-2, CP 331648
(pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
IT **50-78-2**, Aspirin **150322-43-3**, CS 747
(pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
RN 50-78-2 USPATFULL
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)




RN 150322-43-3 USPATFULL
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




L28 ANSWER 4 OF 37 USPATFULL on STN
AN 2005:5047 USPATFULL
TI Spiro-hydantoin compounds useful as anti-inflammatory agents
IN Dhar, T.G. Murali, Newtown, PA, UNITED STATES
Potin, Dominique, Epone, FRANCE
Blandine Maillet, Magali Jeannine, Suresnes, FRANCE
Launay, Michele, Rueil Malmaison, FRANCE
Nicolai, Eric Antoine, Rueil Malmaison, FRANCE
Iwanowicz, Edwin J., Cranbury, NJ, UNITED STATES
PI US 2005004153 A1 20050106
AI US 2004-869292 A1 20040616 (10)
RLI Division of Ser. No. US 2002-262182, filed on 1 Oct 2002, PENDING
PRAI US 2001-326361P 20011001 (60) <--
US 2002-354113P 20020204 (60)
US 2002-400259P 20020801 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 28
ECL Exemplary Claim: CLM-01-29
DRWN No Drawings
LN.CNT 4430
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), and pharmaceutically-acceptable salts,

hydrates, enantiomers, and diastereomers, and prodrugs thereof, ##STR1##

are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR.sub.4b; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R.sub.2, R.sub.4a, R.sub.4b, and R.sub.4c are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-326361P 20011001 (60) <--
DETD [0209] Examples of suitable other anti-inflammatory agents with which the inventive compounds may be used include **aspirin**, cromolyn, nedocromil, theophylline, zileuton, zafirlukast, montelukast, pranlukast, indomethacin, and lipoxygenase inhibitors; non-steroidal antiinflammatory drugs (NSAIDs) (such as ibuprofen and naproxin);. . .
DETD . . . U.S. application Ser. No. 09/729,731, filed Dec. 5, 2000); and gap-junction modulators such as connexions; anticoagulant or antithrombotic agents including **aspirin**, warfarin, ximelagtran, low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin), anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, and tirofiban), thromboxane receptor antagonists (e.g., ifetroban), P2Y.sub.1 and P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**, and **aspirin**/clopidogrel combinations), and Factor Xa inhibitors (e.g., fondaprinux); and diuretics such as sodium-hydrogen exchange inhibitors, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide,. . .

L28 ANSWER 5 OF 37 USPATFULL on STN
AN 2004:328072 USPATFULL
TI Spiro-hydantoin compounds useful as anti-inflammatory agents
IN Dhar, T.G. Murali, Newtown, PA, UNITED STATES
Potin, Dominique, Epone, FRANCE
Maillet, Magali Jeannine Blandine, Suresnes, FRANCE
Launay, Michele, Rueil Malmaison, FRANCE
Nicolai, Eric Antoine, Rueil Malmaison, FRANCE
Iwanowicz, Edwin J., Cranbury, NJ, UNITED STATES
PI US 2004259897 A1 20041223
AI US 2004-869289 A1 20040616 (10)
RLI Continuation of Ser. No. US 2002-262182, filed on 1 Oct 2002, PENDING
PRAI US 2001-326361P 20011001 (60) <--
US 2002-354113P 20020204 (60)
US 2002-400259P 20020801 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, ##STR1##

are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents,

wherein L and K are O or S; Z is N or CR.sub.4b; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R.sub.2, R.sub.4a, R.sub.4b, and R.sub.4c are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-326361P 20011001 (60) <--
DETD [0209] Examplestof suitable other anti-inflammatory agents with which the inventive compounds may de used include **aspirin**, cromolyn, nedocromil, theophylline, zileuton, zafirlukost, montelukast, pranlukast, indomethacin, and lipoxygenase inhibitors; non-stl roidal antiinflammatory drugs (NSAIDs) (such as ibuprofen and. . .
DETD . . . U.S. application Ser. No. 09/729,731, filed Dec. 5, 2000); and gap-junction modulators such as connexions; anticoagulant or antithrombotic agents including **aspirin**, warfarin, ximelagtran, low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin), anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, and tirofiban), thromboxane receptor antagonists (e.g., ifetroban), P2Y, and P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**, and **aspirin**/clopidogrel combinations), and Factor Xa inhibitors (e.g., fondaprinux); and diuretics such as sodium-hydrogen exchange inhibitors, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide,. . .

L28 ANSWER 6 OF 37 USPATFULL on STN
AN 2004:315244 USPATFULL
TI Spiro-hydantoin compounds useful as anti-inflammatory agents
IN Dhar, T.G. Murali, Newtown, PA, UNITED STATES
Potin, Dominique, Epone, FRANCE
Maillet, Magali Jeannine Blandine, Suresnes, FRANCE
Launay, Michele, Rueil Malmaison, FRANCE
Nicolai, Eric Antoine, Rueil Malmaison, FRANCE
Iwanowicz, Edwin J., Cranbury, NJ, UNITED STATES
PI US 2004248920 A1 20041209
AI US 2004-852576 A1 20040524 (10)
RLI Division of Ser. No. US 2002-262182, filed on 1 Oct 2002, PENDING
PRAI US 2001-326361P 20011001 (60) <--
US 2002-354113P 20020204 (60)
US 2002-400259P 20020801 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, ##STR1##

are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR.sub.4b; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and

R.sub.2, R.sub.4a, R.sub.4b, and R.sub.4c are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-326361P 20011001 (60) <--
DETD [0209] Examples of suitable other anti-inflammatory agents with which the inventive compounds may be used include **aspirin**, cromolyn, nedocromil, theophylline, zileuton, zafirlukast, montelukast, pranlukast, indomethacin, and lipoxygenase inhibitors; non-steroidal antiinflammatory drugs (NSAIDs) (such as ibuprofen and naproxin);. . .
DETD . . . U.S. application Ser. No. 09/729,731, filed Dec. 5, 2000); and gap-junction modulators such as connexions; anticoagulant or antithrombotic agents including **aspirin**, warfarin, ximelagtran, low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin), anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, and tirofiban), thromboxane receptor antagonists (e.g., ifetroban), P2Y.sub.1 and P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**, and **aspirin**/clopidogrel combinations), and Factor Xa inhibitors (e.g., fondaprinux); and diuretics such as sodium-hydrogen exchange inhibitors, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide,. . .

L28 ANSWER 7 OF 37 USPATFULL on STN
AN 2004:227938 USPATFULL
TI Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Pickering, Dacia A., Lawrenceville, NJ, UNITED STATES
Giese, Soren, New Hope, PA, UNITED STATES
Fura, Aberra, Lawrenceville, NJ, UNITED STATES
Li, Wenying, Middletown, CT, UNITED STATES
Patel, Ramesh N., Bridgewater, NJ, UNITED STATES
Hanson, Ronald L., Morris Plains, NJ, UNITED STATES
PI US 2004176324 A1 20040909
AI US 2001-885381 A1 20010620 (9) <--
PRAI US 2000-233519P 20000919 (60) <--
US 2001-284730P 20010418 (60) <--
US 2001-284438P 20010418 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-885381 A1 20010620 (9) <--
PRAI US 2000-233519P 20000919 (60) <--
PRAI US 2001-284730P 20010418 (60) <--
PRAI US 2001-284438P 20010418 (60) <--
SUMM . . . the compounds of the present invention include prednisone,

dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®) integrin antagonists, alpha-4. . .

SUMM . . . combination with the compounds of the present invention include GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747** ), thromboxane receptor antagonists (e.g., ifetroban), **aspirin** , and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

L28 ANSWER 8 OF 37 USPATFULL on STN
AN 2004:166025 USPATFULL
TI Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
IN Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES
Tellew, John E., Pennington, NJ, UNITED STATES
Macor, John E., Flemington, NJ, UNITED STATES
Gu, Zhengxiang, Princeton, NJ, UNITED STATES
PI US 2004127515 A1 20040701
US 6852745 B2 20050208
AI US 2003-672572 A1 20030926 (10)
RLI Division of Ser. No. US 2000-737201, filed on 14 Dec 2000, GRANTED, Pat. No. US 6638937 Continuation-in-part of Ser. No. US 2000-643640, filed on 22 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-604322, filed on 26 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-513779, filed on 25 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-481197, filed on 11 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-464037, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-345392, filed on 1 Jul 1999, ABANDONED
PRAI US 1998-91847P 19980706 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 108
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 1998-91847P 19980706 (60) <--
SUMM . . . factor (PAF) antagonists; anti-platelet agents such as GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and **CS-747**), and **aspirin**; anticoagulants such as warfarin, low molecular weight heparins such as enoxaparin, Factor VIIa inhibitors, and Factor Xa inhibitors such as. . . U.S. Ser. No. 09/390,275 filed Sep. 7, 1999 (attorney docket LA 24b); digitalis; ouabian; non-steroidal antiinflammatory drugs (NSAIDS) such as **aspirin** and ibuprofen; phosphodiesterase inhibitors such as PDE

III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil); protein tyrosine kinase. . .

CLM What is claimed is:
86. The method of claim 85 wherein said anti-platelet agent is selected from clopidigrel, ticlopidine, **CS-747** or **aspirin.**

100. The pharmaceutical composition of claim 99 wherein said anti-platelet agent is selected from clopidigrel, ticlopidine, **CS-747** or **aspirin.**

L28 ANSWER 9 OF 37 USPATFULL on STN
AN 2004:139799 USPATFULL
TI Rail stent
IN Solovay, Kenneth S., Weston, FL, UNITED STATES
Jacobs, Thomas P., Fort Lauderdale, FL, UNITED STATES
PA GMP/Cardiac Care, Inc., Fort Lauderdale, FL (U.S. corporation)
PI US 2004106975 A1 20040603
AI US 2003-713873 A1 20031114 (10)
RLI Continuation-in-part of Ser. No. US 2002-100986, filed on 20 Mar 2002, PENDING
PRAI US 2001-276913P 20010320 (60) <--
US 2002-426366P 20021115 (60)
DT Utility
FS APPLICATION
LREP GMP COMPANIES, INC., ONE EAST BROWARD BLVD., SUITE 1701, FORT LAUDERDALE, FL, 33301
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 1721
AB A stent with a plurality of support elements that are deployable within a body for supporting a vessel or other body structure. The stent includes first and second terminal ends and a length extending between the terminal ends. Support rails extend between the terminal ends and through the support members in a direction parallel to the longitudinal axis of the stent. The support elements can include openings for receiving the rails. The rails can include curved end sections that aid in deployment of the stent into a vessel.

PRAI US 2001-276913P 20010320 (60) <--
DETD . . . sodium apolate, thrombocid, tioclomarol, warfarin, aprosulate sodium, ART 123, bivalirudin, BMS 189090, BMS 186282, BMS 189664, BMS 191032, corsevin M, **CS 747**, curdlan sulfate, DPC 423, DX 9065a, efegatran, fondaparinux sodium, GR 144053, inogatran, LB 30057, melagatran, MR 33, napsagatran, NSL 9403,. . . proteinase inhibitor, pamiteplase, staphylokinase, and tenecteplase; antifibrinolytics include, e.g., aminocaproic acid; hemorheologic agents include, e.g., pentoxifylline; antiplatelet agents include, e.g., **aspirin**, ticlopidine, abciximab, clopidogrel, eptifibatide, tirofiban, and glycoprotein IIb/IIa inhibitors, argatroban, cilostazole, cloricromene, dalteparin, daltroban, defibrotide, dipyridamole, enoxaparin, iloprost, indobufen, isbogrel,. . .

L28 ANSWER 10 OF 37 USPATFULL on STN
AN 2004:139657 USPATFULL
TI Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
IN San, Natesan Murug, Princeton Junction, NJ, UNITED STATES

Tellew, John E., Pennington, NJ, UNITED STATES
Macor, John E., Flemington, NJ, UNITED STATES
Gu, Zhengxiang, Princeton, NJ, UNITED STATES
PI US 2004106833 A1 20040603
US 6835741 B2 20041228
AI US 2003-673100 A1 20030926 (10)
RLI Division of Ser. No. US 2000-737201, filed on 14 Dec 2000, GRANTED, Pat. No. US 6638937 Continuation-in-part of Ser. No. US 2000-643640, filed on 22 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-604322, filed on 26 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-513779, filed on 25 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-481197, filed on 11 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-464037, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-345392, filed on 1 Jul 1999, ABANDONED
PRAI US 1998-91847P 19980706 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 108
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8664
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 1998-91847P 19980706 (60) <--
SUMM . . . factor (PAF) antagonists; anti-platelet agents such as GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and **CS-747**), and **aspirin**; anticoagulants such as warfarin, low molecular weight heparins such as enoxaparin, Factor VIIa inhibitors, and Factor Xa inhibitors such as. . . U.S. Ser. No. 09/390,275 filed Sep. 7, 1999 (attorney docket LA 24b); digitalis; ouabian; non-steroidal antiinflammatory drugs (NSAIDS) such as **aspirin** and ibuprofen; phosphodiesterase inhibitors such as PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil); protein tyrosine kinase. . .
CLM What is claimed is:
86. The method of claim 85 wherein said anti-platelet agent is selected from clopidigrel, ticlopidine, **CS-747** or **aspirin.**

100. The pharmaceutical composition of claim 99 wherein said anti-platelet agent is selected from clopidigrel, ticlopidine, **CS-747** or **aspirin.**

L28 ANSWER 11 OF 37 USPATFULL on STN
AN 2004:121143 USPATFULL
TI Bicyclic modulators of androgen receptor function
IN Hamann, Lawrence, Cherry Hill, NJ, UNITED STATES
Augeri, David, Princeton, NJ, UNITED STATES
PI US 2004092559 A1 20040513

AI US 2003-685020 A1 20031014 (10)
RLI Division of Ser. No. US 2002-209461, filed on 31 Jul 2002, GRANTED, Pat. No. US 6670386
PRAI US 2001-309059P 20010731 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of the formula I ##STR1##

wherein the substitutents are as described herein.

Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-309059P 20010731 (60) <--
SUMM . . . the compounds of the present invention include prednisone, dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®), integrin antagonists, alpha4. . .
SUMM . . . combination with the compounds of the present invention include GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747** ), thromboxane receptor antagonists (e.g., ifetroban), **aspirin** , and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

L28 ANSWER 12 OF 37 USPATFULL on STN
AN 2004:101736 USPATFULL
TI Fused cyclic modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Shan, Weifang, Princeton, NJ, UNITED STATES
Giese, Soren, New Hope, PA, UNITED STATES
Harikrishnan, Lalgudi S., Princeton, NJ, UNITED STATES
PI US 2004077606 A1 20040422
AI US 2002-322306 A1 20021218 (10)
RLI Continuation-in-part of Ser. No. US 2001-25233, filed on 19 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-885798, filed on 20 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-885827, filed on 20 Jun 2001, PENDING
PRAI US 2000-214392P 20000628 (60) <--
US 2001-284438P 20010418 (60) <--
US 2001-284617P 20010418 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 26

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2000-214392P 20000628 (60) <--
PRAI US 2001-284438P 20010418 (60) <--
PRAI US 2001-284617P 20010418 (60) <--
SUMM . . . the compounds of the present invention include prednisone, dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®) integrin antagonists, alpha-4. . .
SUMM . . . combination with the compounds of the present invention include GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747** ), thromboxane receptor antagonists (e.g., ifetroban), **aspirin** , and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

L28 ANSWER 13 OF 37 USPATFULL on STN
AN 2004:83231 USPATFULL
TI Heterocyclic dihydropyrimidine compounds
IN Atwal, Karnail S., Newtown, PA, UNITED STATES
Vaccaro, Wayne, Yardley, PA, UNITED STATES
Lloyd, John, Yardley, PA, UNITED STATES
Finlay, Heather, Lawrenceville, NJ, UNITED STATES
Yan, Lin, Princeton, NJ, UNITED STATES
Bhandaru, Rao S., Belle Mead, NJ, UNITED STATES
PI US 2004063687 A1 20040401
AI US 2003-660878 A1 20030912 (10)
RLI Division of Ser. No. US 2000-729731, filed on 5 Dec 2000, PENDING
PRAI US 2000-236037P 20000928 (60) <--
US 1999-169091P 19991206 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K.sub.v1 subfamily of voltage gated K.sup.+ channels, especially inhibitors K.sub.v1.5 which has been linked to the ultra-rapidly activating delayed rectifier K.sup.+ current I.sub.Kur), methods of using such compounds in the prevention and treatment of arrhythmia and I.sub.Kur-associated conditions, and pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2000-236037P 20000928 (60) <--

PRAI US 1999-169091P 19991206 (60) <--
SUMM . . . L-type and T-type) such as diltiazem, verapamil, nifedipine, amlodipine and mybefradil; Cyclooxygenase inibitors (i.e., COX-1 and/or COX-2 inhibitors) such as **aspirin**, indomethacin, ibuprofen, piroxicam, naproxen, celebrex, vioxx and NSAIDs; anti-platelet agents such as GPIIb/IIIa blockers (e.g., abciximab, eptifibatide and tirofiban), P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine and **CS-747**), thromboxane receptor antagonists (e.g., ifetroban), **aspirin**, and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin**; diruetics such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene,. . .
CLM What is claimed is:
31. The pharmaceutical composition of claim 30 wherein the anti-platelet agent is selected from clopidogrel, ifetroban and **aspirin.**

L28 ANSWER 14 OF 37 USPATFULL on STN
AN 2004:70727 USPATFULL
TI Acridone inhibitors of IMPDH enzyme
IN Iwanowicz, Edwin J., West Windsor, NJ, UNITED STATES
Watterson, Scott H., Pennington, NJ, UNITED STATES
Chen, Ping, Belle Mead, NJ, UNITED STATES
Dhar, T. G. Murali, Newtown, PA, UNITED STATES
Gu, Henry H., Bordentown, NJ, UNITED STATES
Zhao, Yufen, Pennington, NJ, UNITED STATES
PI US 2004053955 A1 20040318
AI US 2002-324306 A1 20021220 (10)
PRAI US 2001-343234P 20011221 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), ##STR1##

wherein R.sup.3 is selected from H, OH and NH.sub.2; R.sup.30 is selected from .dbd.O and .dbd.S; W is --C(.dbd.O)--, --S(.dbd.O)--, or --S(O).sub.2--; or W may be --CH.sub.2-- if X is --C(.dbd.O)--; X is selected from --CH.sub.2--, --N(R.sup.4)--, and --O--, except that when W is --CH.sub.2--, X is --C(.dbd.O)--; Y is a bond or --C(R.sup.40)(R.sup.45)--; Q is a linker; Z is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and R.sup.1, R.sup.2, R.sup.24, and R.sup.25 are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-343234P 20011221 (60) <--
SUMM [0133] Examples of suitable other anti-inflammatory agents with which the inventive compounds may be used include **aspirin**, cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast, pranleukast, indomethacin, and lipoxygenase inhibitors; non-steroidal antiinflammatory drugs (NSAIDs) (such as ibuprofen, celecoxib, rofecoxib,. . .

SUMM . . . U.S. application Ser. No. 09/729,731, filed Dec. 5, 2000); and gap-junction modulators such as connexions; anticoagulant or antithrombotic agents including **aspirin**, warfarin, ximelagtran, low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin), anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, and tirofiban), thromboxane receptor antagonists (e.g., ifetroban), P2Y.sub.1 and P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**, and **aspirin**/clopidogrel combinations), and Factor Xa inhibitors (e.g., fondaprinux); and diuretics such as sodium-hydrogen exchange inhibitors, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide,. . .

L28 ANSWER 15 OF 37 USPATFULL on STN
AN 2004:51602 USPATFULL
TI (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
IN Atwal, Karnail S., Pennington, NJ, UNITED STATES
Grover, Gary J., Stockton, NJ, UNITED STATES
Ding, Charles Z., Dallas, TX, UNITED STATES
Stein, Philip D., Pennington, NJ, UNITED STATES
Lloyd, John, Yardley, PA, UNITED STATES
Ahmad, Saleem, Wall, NJ, UNITED STATES
Hamann, Lawrence G., Cherry Hill, NJ, UNITED STATES
Green, David, Haverhill, MA, UNITED STATES
Ferrara, Francis N., Bedminster, NJ, UNITED STATES
PI US 2004039033 A1 20040226
AI US 2002-315818 A1 20021210 (10)
PRAI US 2001-339108P 20011210 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), and pharmaceutically acceptable salts thereof, ##STR1##

are useful for modulating mitochondrial F.sub.1F.sub.0 ATPase activity and treating ischemic conditions including myocardial infarction, congestive heart failure, and cardiac arrhythmias.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-339108P 20011210 (60) <--
SUMM [0135] For example, the inventive compounds may be used in combination with **aspirin**, clopidogrel, ticlopidine or **CS-747**, warfarin, and low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin). Other suitable therapeutic agents in combination with which. . .
SUMM . . . flunisolide or dexamethasone; prednisone; dexamethasone; enbrel; protien tyrosine kinase (PTK) inhibitors; cyclooxygenase inhibitors (including NSAIDs, and COX-1 and/or COX-2 inhibitors); **aspirin**; or indomethacin; lipoxygenase inhibitors; chemokine receptor modulators (including CCR1, CCR2, CCR3, CXCR2 receptor antagonists); secretory and cytosolic phospholipase A2 inhibitors;. . .
SUMM [0147] anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g.,

abciximab, eptifibatide, tirofiban); P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**); or thromboxane receptor antagonists (e.g., ifetroban);

SUMM [0160] phosphodiesterase (PDE) inhibitors including dipyridamole, cilostazol, or sildenafil, or PDE inhibitors in combination with **aspirin**, ifetroban, picotamide, ketanserin, clopidogrel, and/or thromboxane receptor antagonists or thromboxane A synthetase inhibitors (such as picotamide);

CLM What is claimed is:

. . . vasopepsidase inhibitors; and (c) a platelet inhibitor selected from one or more of aGPIIb/IIIa blocker, P2Y12 antagonist, thromboxane receptor antagonist, **aspirin**, and plavix.

L28 ANSWER 16 OF 37 USPATFULL on STN

AN 2004:31871 USPATFULL

TI Medicinal compositions containing **aspirin**

IN Asai, Fumitoshi, Tokyo, JAPAN
Sugidachi, Atsuhiro, Kawasaki-shi, JAPAN
Ogawa, Taketoshi, Tokyo, JAPAN
Inoue, Teruhiko, Ube-shi, JAPAN

PA SANKYO COMPANY, LIMITED, Tokyo, JAPAN (non-U.S. corporation)
UBE INDUSTRIES, LTD,, Yamaguchi, JAPAN (non-U.S. corporation)

PI US 2004024013 A1 20040205

AI US 2003-600266 A1 20030620 (10)

RLI Continuation of Ser. No. WO 2001-JP11201, filed on 20 Dec 2001, UNKNOWN

PRAI JP 2000-392983 20001225 <--

DT Utility

FS APPLICATION

LREP FRISHAUF, HOLTZ, GOODMAN & CHICK, PC, 767 THIRD AVENUE, 25TH FLOOR, NEW YORK, NY, 10017-2023

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 341

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A combination of **2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Medicinal compositions containing **aspirin**

PRAI JP 2000-392983 20001225 <--

AB A combination of **2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by. . .

SUMM [0002] This invention relates to pharmaceutical compositions containing **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno**

**[3,2-c]pyridine** or a
pharmaceutically acceptable salt thereof, and **aspirin**, as
active ingredients [particularly pharmaceutical compositions for
prevention or treatment (particularly for treatment) of diseases caused
by thrombus or embolus]; to the use of **2-acetoxy-**
**5-α -cyclopropylcarbonyl-2-**
**fluorobenzyl)-4,5,6,7-**
**tetrahydrothieno[3,2-c]**
**pyridine** or a pharmaceutically acceptable salt thereof and
**aspirin** for the manufacture of pharmaceutical compositions for
prevention or treatment (particularly for treatment) of diseases caused
by thrombus or embolus;. . . (particularly to methods for the
treatment) of diseases caused by thrombus or embolus by administration
of an effective amount of **2-acetoxy-5-(.**
**alpha.-cyclopropylcarbonyl-2-**
**fluorobenzyl)-4,5,6,7-**
**tetrahydrothieno[3,2-c]**
**pyridine** or a pharmaceutically acceptable salt thereof and
**aspirin** to warm-blooded animals (particularly humans).

SUMM [0003] **2-Acetoxy-5-(α -**
**cyclopropylcarbonyl-2-fluorobenzyl)-**
**4,5,6,7-tetrahydrothieno**
**[3,2-c]pyridine** has been
described in the Japanese Patent Application Publication No. Hei
6-41139, and possesses potent inhibitory activity against platelet
aggregation. Furthermore, **aspirin** is well known to have an
inhibiting activity against platelet aggregation, although the activity
is low. However, pharmaceutical compositions containing. . .

SUMM . . . inhibitory activity against platelet aggregation and have found
that the problems described above are solved by using pharmaceutical
compositions comprising **2-acetoxy-5-(.**
**alpha.-cyclopropylcarbonyl-2-**
**fluorobenzyl)-4,5,6,7-**
**tetrahydrothieno[3,2-c]**
**pyridine** or a pharmaceutically acceptable salt thereof and
**aspirin.**

SUMM [0005] The present invention provides pharmaceutical compositions
containing **2-acetoxy-5-(α -**
**cyclopropylcarbonyl-2-fluorobenzyl)-**
**4,5,6,7-tetrahydrothieno**
**[3,2-c]pyridine** or a
pharmaceutically acceptable salt thereof and **aspirin** as active
ingredients [particularly pharmaceutical compositions for prevention or
treatment (particularly for treatment) of diseases caused by thrombus or
embolus]; the use of **2-acetoxy-5-(.**
**alpha.-cyclopropylcarbonyl-2-**
**fluorobenzyl)-4,5,6,7-**
**tetrahydrothieno[3,2-c]**
**pyridine** or a pharmaceutically acceptable salt thereof, and
**aspirin**, for the manufacture of pharmaceutical compositions
[particularly pharmaceutical compositions for prevention or treatment
(particularly for treatment) of diseases caused by. . . or treatment
(particularly methods for treatment) of diseases caused by thrombus or
embolus by administration of an effective amount of **2-**
**acetoxy-5-(α -**
**cyclopropylcarbonyl-2-fluorobenzyl)-**
**4,5,6,7-tetrahydrothieno**
**[3,2-c]pyridine** or a
pharmaceutically acceptable salt thereof, and **aspirin**, to
warm-blooded animals (particularly humans), simultaneously or

sequentially.

SUMM [0006] **2-Acetoxy-5-(α - cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine**, and pharmaceutically acceptable salts thereof, which is one of the active ingredients of the present invention, is a known compound.. . .

SUMM [0007] The pharmaceutically acceptable salts of **2-acetoxy-5-(α - cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine** may be, for example, hydrohalogenic acid salts such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide; nitrate; perchlorate; sulfate; phosphate; C.sub.1-C.sub.4 alkanesulfonates. . .

SUMM [0008] When one of the active ingredients of the present invention, **2-acetoxy-5-(α - cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, is allowed to stand so that it is open to the atmosphere, it may. . .

SUMM [0009] Further, one of the active ingredients of the present invention, **2-acetoxy-5-(α - cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, may absorb some kinds of organic solvents and may form solvates in some cases,. . .

SUMM [0010] Furthermore, since **2-acetoxy-5-(. alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c] pyridine** has an asymmetric carbon atom, optical isomers exist based on the asymmetric carbon atom. These optical isomers are also included. . .

SUMM [0011] The other active ingredient, **aspirin**, is a well-known compound, as an analgesic antipyretic.

SUMM . . . the present invention (particularly pharmaceutical compositions for the prevention or treatment of diseases caused by thrombus or embolus) which contain **2-acetoxy-5-(. alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c] pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, as active ingredients, possess excellent inhibitory activity against platelet aggregation and thrombogenesis with short onset latency and low toxicity. Thus. . .

SUMM [0013] According to the present invention, the use in combination of **2-acetoxy-5-(α - cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, results in more potent effectiveness than the use of each component alone. Furthermore, plasma levels of these agents do not. . .

SUMM . . . of the previously administered component. However, it is convenient clinically that both components are administered at the same time. Thus **2-acetoxy-5-(α - cyclopropylcarbonyl-2-fluorobenzyl)-**

**4,5,6,7-tetrahydrothieno**
**[3,2-c]pyridine** or a
pharmaceutically acceptable salt thereof and **aspirin** are simultaneously administered as a combination drug. In the case that both agents cannot be mixed technically, each component can. . .

SUMM [0015] The route for administration of **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, which is employed in the present invention, is generally the oral route. However, other routes, for example, intravenous administration, can. . .

SUMM [0017] The dose and the dose ratio of **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or pharmaceutically acceptable salt thereof, and **aspirin**, can be widely altered based on several factors such as activity of each compound, and the symptoms, age and body. . .

SUMM [0019] Generally, the dose ratio of **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or pharmaceutically acceptable salt thereof, and **aspirin**, is from 1:500 to 500:1 as their weight ratio.

DETD [0023] **2-Acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** was synthesized according to the method described in the Specification of Japanese Patent Application Publication No. Hei 6-41139 and was used, while **aspirin** was purchased from Sigma Chemical Co. and was used. Both compounds were suspended in 5% (w/v) gum arabic solution, and. . .

DETD . . . shown in Table 1. The results in the table are expressed as the average weight±SE (n=6).

TABLE 1

Compounds

| Compound A (mg/kg) | **Aspirin** (mg/kg) | Thrombus Weight (mg) | Inhibition Rate (%) |
|---|---|---|---|
| 0 | 0 | 52.3 ± 1.2 | -- |
| 0 | 10 | 46.6 ± 2.8 | 12.3 ± 4.4 |
| 0.3 | 0. . . ± 2.1 | 28.3 ± 4.0 | |
| 0.3 | 10 | 30.5 ± 3.5 | 41.8 ± 6.6 |
| 0.6 | 10 | 23.2 ± 3.8 | 55.7 ± 7.2 |

Compound A: **2-Acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine**

DETD [0028]

(Formulation 1)

Tablets

Compound A 10.0 mg

| | |
|---|---|
| **Aspirin** | 12.5 mg |
| Lactose | 175.5 mg |
| Corn starch | 50.0 mg |
| Magnesium stearate | 2.0 mg |
| Total | 250 mg |

CLM What is claimed is:

1. A pharmaceutical composition comprising **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, in a ratio by weight of 1:500 to 500:1.

3. The pharmaceutical composition of claim 1 wherein the **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** is in the form of a pharmaceutically acceptable salt.

6. A method for the prevention of diseases caused by thrombus or embolus, comprising administering a pharmaceutical composition comprising **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

9. A method for the treatment of diseases caused by thrombus or embolus, comprising administering a pharmaceutical composition comprising **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

. . . method for the treatment of a patient undergoing stenting, angioplasty, and/or to prevent restenosis comprising administering a pharmaceutical composition comprising **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine** or a pharmaceutically acceptable salt thereof, and **aspirin**, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

IT **50-78-2**, Aspirin **150322-43-3 389574-19-0 389574-20-3**
(medicinal compns. containing aspirin and thienopyridinylethanone derivative)

IT **50-78-2**, Aspirin **150322-43-3 389574-19-0 389574-20-3**
(medicinal compns. containing aspirin and thienopyridinylethanone derivative)

RN 50-78-2 USPATFULL

CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)



RN 150322-43-3 USPATFULL
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 389574-19-0 USPATFULL
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 389574-20-3 USPATFULL
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 150322-43-3
CMF C20 H20 F N O3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L28 ANSWER 17 OF 37 USPATFULL on STN
AN 2004:13475 USPATFULL
TI Spiro-hydantoin compounds useful as anti-inflammatory agents
IN Dhar, T. G. Murali, Newtown, PA, UNITED STATES
Potin, Dominique, Epone, FRANCE
Maillet, Magali Jeannine Blandine, Suresnes, FRANCE
Launay, Michele, Rueil Malmaison, FRANCE
Nicolai, Eric Antoine, Rueil Malmaison, FRANCE
Iwanowicz, Edwin J., Cranbury, NJ, UNITED STATES
PI US 2004009998 A1 20040115
AI US 2002-262182 A1 20021001 (10)
PRAI US 2001-326361P 20011001 (60) <--
US 2002-354113P 20020204 (60)
US 2002-400259P 20020801 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, ##STR1##

are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR.sub.4b; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R.sub.2 R.sub.4a, R.sub.4b, and R.sub.4c are as defined in the

specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-326361P 20011001 (60) <--
SUMM [0209] Examples of suitable other anti-inflammatory agents with which the inventive compounds may be used include **aspirin**, cromolyn, nedocromil, theophylline, zileuton, zafirlukast, montelukast, pranlukast, indomethacin, and lipoxygenase inhibitors; non-steroidal antiinflammatory drugs (NSAIDs) (such as ibuprofen and naproxin);. . .
SUMM . . . U.S. application Ser. No. 09/729,731, filed Dec. 5, 2000); and gap-junction modulators such as connexions; anticoagulant or antithrombotic agents including **aspirin**, warfarin, ximelagtran, low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin), anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, and tirofiban), thromboxane receptor antagonists (e.g., ifetroban), P2Y.sub.1 and P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**, and **aspirin**/clopidogrel combinations), and Factor Xa inhibitors (e.g., fondaprinux); and diuretics such as sodium-hydrogen exchange inhibitors, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide,. . .

L28 ANSWER 18 OF 37 USPATFULL on STN
AN 2003:302869 USPATFULL
TI Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
IN Hermsmeier, Mark Alden, Somerville, NJ, United States
Rawlins, David B., Morrisville, PA, United States
Wityak, John, Robbinsville, NJ, United States
PA Bristol-Myers Squibb Co., Princeton, NJ, United States (U.S. corporation)
PI US 6649606 B1 20031118
AI US 2002-289671 20021107 (10)
PRAI US 2001-346377P 20011109 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davis, Zinna Northington
LREP Duncan, Laurelee A.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Tetrahydroisoquinoline analogs are provided which are modulators of chemokine receptor activity.

The tetrahdroisoquinoline analogs thereof have the structure ##STR1##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.3a, X.sub.1, X.sub.2, X.sub.3, X.sub.4, m, n and p are as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-346377P 20011109 (60) <--
SUMM . . . the compounds of the present invention include prednisone, dexamethasone, Enbrel, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen, Celebrex, Vioxx), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, integrin antagonists, alpha4 beta7 integrin antagonists, cell adhesion inhibitors,. . .
SUMM . . . combination with the compounds of the present invention include

GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747** ), thromboxane receptor antagonists (e.g., ifetroban), **aspirin** , and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

L28 ANSWER 19 OF 37 USPATFULL on STN
AN 2003:258675 USPATFULL
TI Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Pickering, Dacia A., Lawrenceville, NJ, UNITED STATES
Zhu, Hong, Lawrenceville, NJ, UNITED STATES
PI US 2003181728 A1 20030925
AI US 2002-322276 A1 20021218 (10)
PRAI US 2001-341962P 20011219 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-341962P 20011219 (60) <--
SUMM . . . the compounds of the present invention include prednisone, dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®) integrin antagonists, alpha-4. . .
SUMM . . . combination with the compounds of the present invention include GPIlb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747** ), thromboxane receptor antagonists (e.g., ifetroban), **aspirin** , and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

L28 ANSWER 20 OF 37 USPATFULL on STN
AN 2003:258444 USPATFULL
TI Heterocyclic acridone inhibitors of IMPDH enzyme
IN Chen, Ping, Belle Mead, NJ, UNITED STATES
Dhar, T. G. Murali, Newtown, PA, UNITED STATES
Iwanowicz, Edwin J., West Windsor, NJ, UNITED STATES
Watterson, Scott H., Pennington, NJ, UNITED STATES
Gu, Henry, Bordentown, NJ, UNITED STATES
Zhao, Yufen, Pennington, NJ, UNITED STATES
PI US 2003181497 A1 20030925
AI US 2002-325009 A1 20021220 (10)
PRAI US 2001-343234P 20011221 (60) <--
DT Utility

FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2064
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), ##STR1##

wherein R.sup.3 is selected from H, OH and NH.sub.2; R.sup.30 is selected from .dbd.O and .dbd.S; W is --C(.dbd.O)--, --S(.dbd.O)--, or --S(O).sub.2--; or W may be --CH.sub.2-- if X is --C(.dbd.O)--; X is selected from --CH.sub.2--, --N(R.sup.4)--, and --O--, except that when W is --CH.sub.2--, X is --C(.dbd.O)--; Y is a bond or --C(R.sup.40)(R.sup.45)--; Q is a linker; Z is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, X.sup.6, X.sup.7, X.sup.8, X.sup.9, X.sup.10 and X.sup.11 are selected such a tricyclic heteroaryl ring system is formed as further defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-343234P 20011221 (60) <--
SUMM [0232] Examples of suitable other anti-inflammatory agents with which the inventive compounds may be used include **aspirin**, cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast, pranleukast, indomethacin, and lipoxygenase inhibitors; non-steroidal antiinflammatory drugs (NSAIDs) (such as ibuprofen, celecoxib, rofecoxib,. . .
SUMM . . . U.S. application Ser. No. 09/729,731, filed Dec. 5, 2000); and gap-junction modulators such as connexions; anticoagulant or antithrombotic agents including **aspirin**, warfarin, ximelagtran, low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin), anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, and tirofiban), thromboxane receptor antagonists (e.g., ifetroban), P2Y.sub.1 and P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**, and **aspirin**/clopidogrel combinations), and Factor Xa inhibitors (e.g., fondaprinux); and diuretics such as sodium-hydrogen exchange inhibitors, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide,. . .

L28 ANSWER 21 OF 37 USPATFULL on STN
AN 2003:238527 USPATFULL
TI Acid derivatives useful as serine protease inhibitors
IN Bisacchi, Gregory S., Ringoes, NJ, UNITED STATES
Sutton, James C., Princeton Junction, NJ, UNITED STATES
Slusarchyk, William A., Skillman, NJ, UNITED STATES
Treuner, Uwe D., Nittendorf, GERMANY, FEDERAL REPUBLIC OF
Zhao, Guohua, Princeton, NJ, UNITED STATES
Cheney, Daniel L., Ringoes, NJ, UNITED STATES
Shi, Yan, Flourtown, PA, UNITED STATES
Wu, Shung C., Princeton, NJ, UNITED STATES
PI US 2003166685 A1 20030904
US 6642252 B2 20031104
AI US 2001-52927 A1 20011107 (10) <--
PRAI US 2000-246392P 20001107 (60) <--
DT Utility
FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), ##STR1##

are useful as serine protease inhibitors, more particularly inhibitors of Factors VIIa, IXa, Xa, and/or XIa, wherein ring B is phenyl or pyridyl, W is preferably C(.dbd.O)NR.sub.4R.sub.5, L is a linker group, X.sub.2 comprises nitrogen or carbon, Z is an optionally-substituted monocyclic or bicyclic ring system, and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-52927 A1 20011107 (10) <--
PRAI US 2000-246392P 20001107 (60) <--
SUMM . . . been researched and developed for use in treating cardiovascular and other diseases. Presently established antithrombotic agents include heparin, coumarin, and **aspirin**, among others. There are, however, limitations with these agents. For example, both heparin and coumarin have a highly-variable dose-related response,. . . serious bleeding. The erratic anticoagulant response of heparin is likely due to its propensity to bind non-specifically to plasma proteins. **Aspirin** has a limited efficacy and at high doses presents a risk of gastrointestinal bleeding. Thrombin inhibitors and their drawbacks are. . .
SUMM . . . also be used in combination with other antithrombotic or anticoagulant drugs such as thrombin inhibitors, platelet aggregation inhibitors such as **aspirin**, clopidogrel, ticlopidine or **CS-747**, warfarin, low molecular weight heparins (such as LOVENOX), GPIIb/GPIIIa blockers. PAI-1 inhibitors such as XR-330 and T-686, inhibitors of α-2-antiplasmin. . . valsartan); and/or ACE/NEP inhibitors (e.g., omapatrilat and gemopatrilat); β-blockers (such as propranolol, nadolol and carvedilol), PDE inhibitors in combination with **aspirin**, ifetroban, picotamide, ketanserin, or clopidogrel and the like. The inventive compounds are also useful in combination with anti-arrhythmic agents such. . .

L28 ANSWER 22 OF 37 USPATFULL on STN
AN 2003:166562 USPATFULL
TI Fused cyclic modulators of nuclear hormone receptor function
IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Balog, James Aaron, Lambertville, NJ, UNITED STATES
Shan, Weifang, Princeton, NJ, UNITED STATES
Giese, Soren, New Hope, PA, UNITED STATES
PI US 2003114420 A1 20030619
AI US 2001-25233 A1 20011219 (10) <--
RLI Continuation-in-part of Ser. No. US 2001-885798, filed on 20 Jun 2001, ABANDONED
PRAI US 2000-214392P 20000628 (60) <--
US 2001-284617P 20010418 (60) <--
US 2001-284438P 20010418 (60) <--
DT Utility
FS APPLICATION
LREP Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000
CLMN Number of Claims: 26

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-25233 A1 20011219 (10) <--
PRAI US 2000-214392P 20000628 (60) <--
PRAI US 2001-284617P 20010418 (60) <--
PRAI US 2001-284438P 20010418 (60) <--
DETD . . . the compounds of the present invention include prednisone, dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®) integrin antagonists, alpha-4. . .
DETD . . . combination with the compounds of the present invention include GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747** ), thromboxane receptor antagonists (e.g., ifetroban), **aspirin** , and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

L28 ANSWER 23 OF 37 USPATFULL on STN
AN 2003:159928 USPATFULL
TI Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IN Ogletree, Martin L., Newtown, PA, UNITED STATES
PI US 2003109543 A1 20030612
AI US 2002-295347 A1 20021115 (10)
RLI Division of Ser. No. US 1999-428611, filed on 27 Oct 1999, GRANTED, Pat. No. US 6509348
PRAI US 1998-106813P 19981103 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1480
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for inhibiting platelet aggregation and thrombus formation by administering to a patient an ADP-receptor blocking antiplatelet drug, such as clopidogrel, in combination with a thromboxane A.sub.2 receptor antagonist, such as ifetroban, and optionally a cholesterol lowering drug, such as an HMG CoA reductase inhibitor, for example, pravastatin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 1998-106813P 19981103 (60) <--
SUMM [0006] WO 97/29753 published Aug. 21, 1997, discloses a pharmaceutical composition containing clopidogrel and **aspirin.**
SUMM [0008] U.S. Pat. No. 5,288,726 (assigned to Sankyo) discloses a platelet

aggregation inhibitor **CS-747** which has the structure and name as follows: ##STR3##

SUMM [0009] **2-acetoxy-5-(α - cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine.**

SUMM . . . Pat. No. 5,312,818 to Rubin et al discloses use of thromboxane A.sub.2 receptor antagonists in combination with anti-inflammatory agents including **aspirin** to prevent or treat ulcerative conditions caused by anti-inflammatory agents.

SUMM . . . method is provided wherein a combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A.sub.2 receptor antagonist, and optionally **aspirin**, is employed to prevent or inhibit platelet aggregation and thrombus formation and to prevent or inhibit any of the disease. . .

SUMM . . . antiplatelet drug suitable for use herein includes antiplatelet drugs which inhibit ADP-induced platelet aggregation and include clopidogrel and/or ticlopidine and/or **CS-747** (described herein), and do not include drugs such as **aspirin** which inhibit platelet aggregation by other mechanisms.

SUMM [0036] The term "**CS-747**" as employed herein includes **2-acetoxy-5-(α (-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine** and pharmaceutically acceptable salts thereof.

SUMM . . . derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, **aspirin**, poly(diallylmethylamine) derivatives such as disclosed in U.S. Pat. No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in. . .

SUMM [0272] **Aspirin** may also be optionally present and may be employed in daily dosages within the range from about 20 mg to. . .

SUMM [0273] The ADP-receptor blocking antiplatelet drug, thromboxane A.sub.2 receptor antagonist and the optional cholesterol lowering agent and optionally **aspirin** may be employed together in the same oral dosage form or in separate oral dosage forms taken at the same. . .

SUMM [0279] Fixed combinations of the ADP-receptor blocking antiplatelet drug, thromboxane A.sub.2 receptor antagonist and optional cholesterol lowering drug and optionally **aspirin** are more convenient and are preferred, especially in tablet or capsule form for oral administration.

DETD . . . activity in all three models. The potential uniqueness of clopidogrel is further underscored by the failure of both ifetroban and **aspirin** (Schumacher et al., 1993a, Schumacher and Steinbacher, J. Cardiovasc. Pharmacol. 22:526-533, 1993) in the vessel injury-induced venous thrombosis model.

DETD . . . effective. This suggests that the thromboxane mechanism does not play the key role in platelet involvement in this platelet-dependent model. **Aspirin**, which also inhibits the thromboxane mechanism, was inactive in both venous thrombosis models. The activity of clopidogrel in these models. . .

DETD . . . the 10-mg/kg clopidogrel dose inhibited this activity by 50%, which is-in the activity range of the clinical dose. Ifetroban (and **aspirin** in previous experiments) failed to inhibit thrombosis in this model. However, the combination of ifetroban and the sub-threshold dose of. . .

CLM What is claimed is:

. . . claim 15 wherein the pharmaceutical combination administered comprises an ADP-receptor blocking agent and a thromboxane A.sub.2 receptor antagonist, and optionally **aspirin**.

L28 ANSWER 24 OF 37 USPATFULL on STN
AN 2003:115837 USPATFULL
TI Sulfonamide lactam inhibitors of FXa and method
IN O'Connor, Stephen P., Newtown, PA, United States
Lawrence, Michael, Yardley, PA, United States
Shi, Yan, Flourtown, PA, United States
Stein, Philip D., Pennington, NJ, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6555542 B1 20030429
AI US 2002-59621 20020129 (10)
PRAI US 2001-264964P 20010130 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Patel, Sudhaker B.
LREP Hermenau, Ronald S.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 5154
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sulfonamide lactams of the following formula ##STR1##

wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.4a, R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7 and R.sup.8 are as described herein, are provided which inhibitors of Factor Xa and are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-264964P 20010130 (60) <--
SUMM . . . also be used in combination with other antithrombotic or anticoagulant drugs such as thrombin inhibitors, platelet aggregation inhibitors such as **aspirin**, clopidogrel, ticlopidine or **CS-747**, warfarin, low molecular weight heparins (such as LOVENOX), GPIIb/GPIIIa blockers, PAI-1 inhibitors such as XR-330 and T-686, inhibitors of α-2-antiplasmin. . . valsartan); and/or ACE/NEP inhibitors (e.g., omapatrilat and gemopatrilat); β-blockers (such as propranolol, nadolol and carvedilol), PDE inhibitors in combination with **aspirin**, ifetroban, picotamide, ketanserin, or clopidogrel and the like. The inventive compounds are also useful in combination with anti-arrhythmic agents such. . .
CLM What is claimed is:
. . . inhibitors, PAI-1 inhibitors, thromboxane receptor antagonists, prostacyclin mimetics, phosphodiesterase inhibitors, fibrinogen antagonists, thromboxane receptor antagonists, thromboxane synthase inhibitors, serotonin-2-receptor antagonists, **aspirin**, hypolipodemic agents, antihypertensive agents, or combinations thereof.

. . . wherein the additional therapeutic agent is streptokinase, releplase, activase, lanoteplase, urokinase, prourokinase, ASPAC, animal salivary gland plasminogen activators, warfarin, clopidogrel, **aspirin**, ticlopidine, ifetroban, XR-330, T-686, dipyridamole, cilostazol, picotamide or ketanserin or combinations thereof.

IT **50-78-2**, Aspirin 58-32-2, Dipyridamole 81-81-2, Warfarin
9002-01-1, Streptokinase 9003-53-6, Aspac 9039-53-6, Urokinase
32828-81-2, Picotamide 55142-85-3, Ticlopidine 73963-72-1, Cilostazol
74050-98-9, Ketanserin 82657-92-9, Prourokinase 105857-23-6, Activase
113665-84-2, Clopidogrel 143443-90-7, Ifetroban 152815-51-5, t-686
156867-02-6, Xr-330 171870-23-8, Lanoteplase
(combination therapy; preparation of arylsulfonamidopiperidones as inhibitors of Factor Xa)
IT **50-78-2**, Aspirin
(combination therapy; preparation of arylsulfonamidopiperidones as inhibitors of Factor Xa)
RN 50-78-2 USPATFULL
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)




L28 ANSWER 25 OF 37 USPATFULL on STN
AN 2003:79166 USPATFULL
TI Bicyclic modulators of androgen receptor function
IN Sun, Chongqing, East Windsor, NJ, UNITED STATES
Robl, Jeffrey A., Newtown, PA, UNITED STATES
Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Wang, Tammy, Lawrenceville, NJ, UNITED STATES
Hamann, Lawrence, Cherry Hill, NJ, UNITED STATES
Augeri, David, Princeton, NJ, UNITED STATES
PI US 2003055094 A1 20030320
US 6670386 B2 20031230
AI US 2002-209461 A1 20020731 (10)
PRAI US 2001-309059P 20010731 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of the formula I ##STR1##

wherein the substitutents are as described herein.

Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-309059P 20010731 (60) <--
SUMM . . . the compounds of the present invention include prednisone, dexamethasone, Enbrel®, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen®, Celebrex®, Vioxx®),

CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, IMPDH inhibitors, such as mycophenolate (CellCept®), integrin antagonists, alpha-4. . .

SUMM . . . combination with the compounds of the present invention include GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747** ), thromboxane receptor antagonists (e.g., ifetroban), **aspirin** , and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

L28 ANSWER 26 OF 37 USPATFULL on STN
AN 2003:57968 USPATFULL
TI Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide
IN Hughes, David E., Pennington, NJ, UNITED STATES
Seidenberg, Beth C., Basking Ridge, NJ, UNITED STATES
PI US 2003040534 A1 20030227
AI US 2002-121520 A1 20020412 (10)
PRAI US 2001-284080P 20010416 (60) <--
DT Utility
FS APPLICATION
LREP Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Endothelin antagoninst N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide surprisingly exists as separable enantiomeric atropisomers. The (+) dextrorotatory atropisomer demonstrates remarkably higher potency than either the (-) levorotatory atropisomer or the racemate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-284080P 20010416 (60) <--
SUMM . . . factor (PAF) antagonists; anti-platelet agents such as GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and **CS-747**), and **aspirin**; anticoagulants such as warfarin, low molecular weight heparins such as enoxaparin, Factor VIIa inhibitors, and Factor Xa inhibitors such as. . . U.S. Ser. No. 09/390,275 filed Sep. 7, 1999 (attorney docket LA 24b); digitalis; ouabian; non-steroidal antiinflammatory drugs (NSAIDS) such as **aspirin** and ibuprofen; phosphodiesterase inhibitors such as PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil); protein tyrosine kinase. . .
CLM What is claimed is:
22. A pharmaceutical composition of claim 19 further comprising at least one antiplatelet agent selected from clopidigrel, ticlopidine, **CS-747** or **aspirin.**

IT **50-78-2**, Aspirin 55142-85-3, Ticlopidine 113665-84-2, Clopidogrel **150322-43-3**, CS 747 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat
(combination with; therapeutic uses of enantiomers of biphenyl isoxazole sulfonamide derivative as endothelin antagonists)
IT **50-78-2**, Aspirin **150322-43-3**, CS 747
(combination with; therapeutic uses of enantiomers of biphenyl

isoxazole sulfonamide derivative as endothelin antagonists)
RN 50-78-2 USPATFULL
CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)



RN 150322-43-3 USPATFULL
CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 27 OF 37 USPATFULL on STN
AN 2003:30941 USPATFULL
TI Heterocyclic dihydropyrimidine compounds
IN Atwal, Karnail S., Newtown, PA, UNITED STATES
Vaccaro, Wayne, Yardley, PA, UNITED STATES
Lloyd, John, Yardley, PA, UNITED STATES
Finlay, Heather, Lawrenceville, NJ, UNITED STATES
Yan, Lin, Princeton, NJ, UNITED STATES
Bhandaru, Rao S., Belle Mead, NJ, UNITED STATES
PI US 2003022890 A1 20030130
US 6706720 B2 20040316
AI US 2000-729731 A1 20001205 (9) <--
PRAI US 2000-236037P 20000928 (60) <--
US 1999-169091P 19991206 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K.sub.v1 subfamily of voltage gated K.sup.+ channels, especially inhibitors K.sub.v1.5 which has been linked to the ultra-rapidly activating delayed rectifier K.sup.+ current I.sub.Kur), methods of using such compounds in the prevention and treatment of arrhythmia and I.sub.Kur-associated conditions, and pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2000-729731 A1 20001205 (9) <--

PRAI US 2000-236037P 20000928 (60) <--
PRAI US 1999-169091P 19991206 (60) <--
SUMM . . . L-type and T-type) such as diltiazem, verapamil, nifedipine, amlodipine and mybefradil; Cyclooxygenase inibitors (i.e., COX-1 and/or COX-2 inhibitors) such as **aspirin**, indomethacin, ibuprofen, piroxicam, naproxen, celebrex, vioxx and NSAIDs; anti-platelet agents such as GPIIb/IIIa blockers (e.g., abciximab, eptifibatide and tirofiban), P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine and **CS-747**), thromboxane receptor antagonists (e.g., ifetroban), **aspirin**, and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin**; diruetics such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene,. . .
CLM What is claimed is:
31. The pharmaceutical composition of claim 30 wherein the anti-platelet agent is selected from clopidogrel, ifetroban and **aspirin.**

L28 ANSWER 28 OF 37 USPATFULL on STN
AN 2003:20233 USPATFULL
TI Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IN Ogletree, Martin L., Newtown, PA, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6509348 B1 20030121
AI US 1999-428611 19991027 (9) <--
PRAI US 1998-106813P 19981103 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fay, Zohreh; Assistant Examiner: Kwon, Brian-Yong
LREP Rodney, Burton
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1341
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for inhibiting platelet aggregation and thrombus formation by administering to a patient an ADP-receptor blocking antiplatelet drug, such as clopidogrel, in combination with a thromboxane A.sub.2 receptor antagonist, such as ifetroban, and optionally a cholesterol lowering drug, such as an HMG CoA reductase inhibitor, for example, pravastatin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 1999-428611 19991027 (9) <--
PRAI US 1998-106813P 19981103 (60) <--
SUMM WO 97/29753 published Aug. 21, 1997, discloses a pharmaceutical composition containing clopidogrel and **aspirin.**
SUMM U.S. Pat. No. 5,288,726 (assigned to Sankyo) discloses a platelet aggregation inhibitor **CS-747** which has the structure and name as follows: ##STR3##
SUMM **2-acetoxy-5-(α -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno [3,2-c]pyridine.**
SUMM . . . Pat. No. 5,312,818 to Rubin et al discloses use of thromboxane

A.sub.2 receptor antagonists in combination with anti-inflammatory agents including **aspirin** to prevent or treat ulcerative conditions caused by anti-inflammatory agents.

SUMM . . . method is provided wherein a combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A.sub.2 receptor antagonist, and optionally **aspirin**, is employed to prevent or inhibit platelet aggregation and thrombus formation and to prevent or inhibit any of the disease. . .

SUMM . . . antiplatelet drug suitable for use herein includes antiplatelet drugs which inhibit ADP-induced platelet aggregation and include clopidogrel and/or ticlopidine and/or **CS-747** (described herein), and do not include drugs such as **aspirin** which inhibit platelet aggregation by other mechanisms.

SUMM The term "**CS-747**" as employed herein includes **2-acetoxy-5-**(α - **cyclopropylcarbonyl-2-fluorobenzyl**)- **4,5,6,7-tetrahydrothieno** [**3,2-c**]**pyridine** and pharmaceutically acceptable salts thereof.

SUMM . . . derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, **aspirin**, oly(diallylmethylamine) derivatives such as disclosed in U.S. Pat. No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in. . .

SUMM **Aspirin** may also be optionally present and may be employed in daily dosages within the range from about 20 mg to. . .

SUMM The ADP-receptor blocking antiplatelet drug, thromboxane A.sub.2 receptor antagonist and the optional cholesterol lowering agent and optionally **aspirin** may be employed together in the same oral dosage form or in separate oral dosage forms taken at the same. . .

SUMM Fixed combinations of the ADP-receptor blocking antiplatelet drug, thromboxane A.sub.2 receptor antagonist and optional cholesterol lowering drug and optionally **aspirin** are more convenient and are preferred, especially in tablet or capsule form for oral administration.

DETD . . . activity in all three models. The potential uniqueness of clopidogrel is further underscored by the failure of both ifetroban and **aspirin** (Schumacher et al., 1993a, Schumacher and Steinbacher, J. Cardiovasc. Pharmacol. 22:526-533, 1993) in the vessel injury-induced venous thrombosis model.

DETD . . . effective. This suggests that the thromboxane mechanism does not play the key role in platelet involvement in this platelet-dependent model. **Aspirin**, which also inhibits the thromboxane mechanism, was inactive in both venous thrombosis models. The activity of clopidogrel in these models. . .

DETD . . . 10-mg/kg clopidogrel dose inhibited this activity by 50%, which is in the activity range of the clinical dose. Ifetroban (and **aspirin** in previous experiments) failed to inhibit thrombosis in this model. However, the combination of ifetroban and the sub-threshold dose of. . .

L28 ANSWER 29 OF 37 USPATFULL on STN
AN 2003:4158 USPATFULL
TI Method for preventing or treating pulmonary inflammation by administering an endothelin antagonist
IN Ounis, Isabelle, Mountain View, CA, UNITED STATES
PI US 2003004199 A1 20030102
AI US 2002-121039 A1 20020411 (10)

PRAI US 2001-283304P 20010412 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Prevention or treatment of disorders of chronic or acute pulmonary inflammation by administration of an endothelin antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI US 2001-283304P 20010412 (60) <--
DETD . . . factor (PAF) antagonists; anti-platelet agents such as GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and **CS-747**), and **aspirin**; anticoagulants such as warfarin, low molecular weight heparins such as enoxaparin, Factor VIIa inhibitors, and Factor Xa inhibitors such as. . . U.S. Ser. No. 09/390,275 filed Sep. 7, 1999 (attorney docket LA 24b); digitalis; ouabian; non-steroidal antiinflammatory drugs (NSAIDS) such as **aspirin** and ibuprofen; phosphodiesterase inhibitors such as PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil); protein tyrosine kinase. . .

L28 ANSWER 30 OF 37 USPATFULL on STN
AN 2002:273417 USPATFULL
TI Acid derivatives useful as serine protease inhibitors
IN Bisacchi, Gregory S., Ringoes, NJ, UNITED STATES
Sutton, James C., Princeton Junction, NJ, UNITED STATES
Wu, Shung C., Princeton, NJ, UNITED STATES
PI US 2002151545 A1 20021017
US 6713467 B2 20040330
AI US 2001-35714 A1 20011107 (10) <--
PRAI US 2000-246391P 20001107 (60) <--
US 2000-246392P 20001107 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula I and II, ##STR1##

or pharmaceutically-acceptable salts thereof, are useful as inhibitors of Factor VIIa, Factor IXa, Factor Xa, Factor FXIa, tryptase, and urokinase, wherein ring B is phenyl or pyridyl, L is a linker, and R.sub.1-R.sub.27, W, Z.sub.1, and Z.sub.2 are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-35714 A1 20011107 (10) <--
PRAI US 2000-246391P 20001107 (60) <--
PRAI US 2000-246392P 20001107 (60) <--
SUMM . . . been researched and developed for use in treating

cardiovascular and other diseases. Presently established antithrombotic agents include heparin, coumarin, and **aspirin**, among others. There are, however, limitations with these agents. For example, both heparin and coumarin have a highly-variable dose-related response,. . . serious bleeding. The erratic anticoagulant response of heparin is likely due to its propensity to bind non-specifically to plasma proteins. **Aspirin** has a limited efficacy and at high doses presents a risk of gastrointestinal bleeding. Thrombin inhibitors and their drawbacks are. . .

SUMM . . . also be used in combination with other antithrombotic or anticoagulant drugs such as thrombin inhibitors, platelet aggregation inhibitors such as **aspirin**, clopidogrel, ticlopidine or **CS-747**, warfarin, low molecular weight heparins (such as LOVENOX), GPIIb/GPIIIa blockers, PAI-1 inhibitors such as XR-330 and T-686, inhibitors of α-2-antiplasmin. . . valsartan); and/or ACE/NEP inhibitors (e.g., omapatrilat and gemopatrilat); β-blockers (such as propranolol, nadolol and carvedilol), PDE inhibitors in combination with **aspirin**, ifetroban, picotamide, ketanserin, or clopidogrel and the like. The inventive compounds are also useful in combination with anti-arrhythmic agents such. . .

L28 ANSWER 31 OF 37 USPATFULL on STN
AN 2002:259599 USPATFULL
TI Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
IN Liu, Chunjian, Pennington, NJ, UNITED STATES
Dhar, T.G. Murali, Newtown, PA, UNITED STATES
Gu, Henry H., Bordentown, NJ, UNITED STATES
Iwanowicz, Edwin J., Cranbury, NJ, UNITED STATES
Leftheris, Katerina, Skillman, NJ, UNITED STATES
Pitts, William J., Newtown, PA, UNITED STATES
Herpin, Timothy F., Princeton, NJ, UNITED STATES
Pi, Zulan, Pennington, NJ, UNITED STATES
Bisacchi, Gregory S., Ringoes, NJ, UNITED STATES
PI US 2002143176 A1 20021003
US 6596747 B2 20030722
AI US 2001-997963 A1 20011129 (9) <--
RLI Continuation-in-part of Ser. No. US 1999-428432, filed on 27 Oct 1999, PENDING
PRAI US 1998-106186P 19981029 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), ##STR1##

are effective as inhibitors of IMPDH enzyme and/or serine protease Factor VIIa, wherein B is a monocyclic or bicyclic carbocyclic or heterocyclic ring, D is a monocyclic or bicyclic carbocyclic or heterocyclic ring except when A is a heterocyclic ring, then D is a heterocyclic ring system, R is hydrogen or C.sub.1-4alkyl, and A, R.sub.1, R.sub.2 and R.sub.4 are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-997963 A1 20011129 (9) <--

PRAI US 1998-106186P 19981029 (60) <--
SUMM [0119] Examples of suitable other anti-inflammatory agents with which the inventive compounds may be used include **aspirin**, non-steroidal antiinflammatory drugs (NSAIDs) (such as ibuprofen and naproxin), TNA-α inhibitors (such as tenidap and rapamycin or derivatives thereof), or. . .
SUMM [0122] Additionally, the inventive compounds may be used in combination with **aspirin**, clopidogrel, ticlopidine or **CS-747**, warfarin, and low molecular weight heparins (such as lovenox, enoxaparain, and dalteparin). Other suitable therapeutic agents in combination with which. . . Vitamin A, Vitamin E, AGI-1067; anti-platelet agents such as GPIIb/GPIIIa blockers, (e.g., abciximab, eptifibatide, tirofiban); P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**); or thromboxane receptor antagonists (e.g., ifetroban); anti-proliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, Prograf), cytotoxic drugs such as azathiprine. . .

L28 ANSWER 32 OF 37 USPATFULL on STN
AN 2002:259449 USPATFULL
TI Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
IN Murugesan, Natesan, Princeton Junction, NJ, UNITED STATES
Tellew, John E., Pennington, NJ, UNITED STATES
Macor, Jhon E., Flemington, NJ, UNITED STATES
Gu, Zhengxiang, Princeton, NJ, UNITED STATES
PI US 2002143024 A1 20021003
US 6638937 B2 20031028
AI US 2000-737201 A1 20001214 (9) <--
RLI Continuation-in-part of Ser. No. US 2000-643640, filed on 22 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-604322, filed on 26 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-513779, filed on 25 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-481197, filed on 11 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-464037, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-345392, filed on 1 Jul 1999, ABANDONED
PRAI US 1998-91847P 19980706 (60) <--
DT Utility
FS APPLICATION
LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 108
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8673
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2000-737201 A1 20001214 (9) <--
PRAI US 1998-91847P 19980706 (60) <--
SUMM . . . factor (PAF) antagonists; anti-platelet agents such as GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and **CS-747**), and **aspirin**; anticoagulants such as warfarin, low molecular weight heparins such as enoxaparin, Factor VIIa

inhibitors, and Factor Xa inhibitors such as. . . U.S. Ser. No. 09/390,275 filed Sep. 7, 1999 (attorney docket LA 24b); digitalis; ouabian; non-steroidal antiinflammatory drugs (NSAIDS) such as **aspirin** and ibuprofen; phosphodiesterase inhibitors such as PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil); protein tyrosine kinase. . .

CLM What is claimed is:

86. The method of claim 85 wherein said anti-platelet agent is selected from clopidigrel, ticlopidine, **CS-747** or **aspirin.**

100. The pharmaceutical composition of claim 99 wherein said anti-platelet agent is selected from clopidigrel, ticlopidine, **CS-747** or **aspirin.**

IT **50-78-2**, Aspirin 52-01-7, Spironolactone 10238-21-8, Glyburide 51384-51-1, Metoprolol 55142-85-3, Ticlopidine 72956-09-3, Carvedilol 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 107724-20-9, Eplerenone 113665-84-2, Clopidogrel 134523-00-5, Atorvastatin 147098-20-2, Zd-4522 147526-32-7, NK 104 **150322-43-3**, Cs-747
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

IT **50-78-2**, Aspirin **150322-43-3**, Cs-747
(preparation of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 50-78-2 USPATFULL

CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)




RN 150322-43-3 USPATFULL

CN Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




L28 ANSWER 33 OF 37 USPATFULL on STN

AN 2002:157678 USPATFULL

TI Method for preventing or treating pain by administering an endothelin antagonist

IN Lebwohl, David E., Madison, CT, UNITED STATES

PI US 2002082285 A1 20020627
US 6573285 B2 20030603

AI US 2001-25158 A1 20011219 (10) <--

PRAI US 2000-257840P 20001221 (60) <--
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 378
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Prevention or treatment of pain by administration of an endothelin antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-25158 A1 20011219 (10) <--
PRAI US 2000-257840P 20001221 (60) <--
DETD . . . factor (PAF) antagonists; anti-platelet agents such as GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and **CS-747**), and **aspirin**; anticoagulants such as warfarin, low molecular weight heparins such as enoxaparin, Factor VIIa inhibitors, and Factor Xa inhibitors such as. . . U.S. Ser. No. 09/390,275 filed Sep. 7, 1999 (attorney docket LA 24b); digitalis; ouabian; non-steroidal antiinflammatory drugs (NSAIDS) such as **aspirin** and ibuprofen; phosphodiesterase inhibitors such as PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil); protein tyrosine kinase. . .

L28 ANSWER 34 OF 37 USPATFULL on STN
AN 2002:85574 USPATFULL
TI Lactam inhibitors of FXa and method
IN Stein, Philip D., Pennington, NJ, UNITED STATES
Shi, Yan, Flourtown, PA, UNITED STATES
O'Connor, Stephen P., Newtown, PA, UNITED STATES
Li, Chi, Randolph, NJ, UNITED STATES
PI US 2002045616 A1 20020418
US 6511973 B2 20030128
AI US 2001-916941 A1 20010727 (9) <--
PRAI US 2000-222498P 20000802 (60) <--
DT Utility
FS APPLICATION
LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1116
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compound of the formula ##STR1##

are inhibitors of the enzyme Factor Xa. These compounds are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-916941 A1 20010727 (9) <--
PRAI US 2000-222498P 20000802 (60) <--
SUMM . . . with the compounds of the present invention include: GPIIb/IIIa blockers (e.g., abciximab, roxifiban, eptifibatide, tirofiban); P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-**

747); thromboxane receptor antagonists (e.g., ifetroban); **aspirin**; and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

SUMM . . . present invention include: prednisone; dexamethasone; enbrel; protien tyrosine kinase (PTK) inhibitors; cyclooxygenase inhibitors (including NSAIDs, and COX-1 and/or COX-2 inhibitors); **aspirin** ; indomethacin; ibuprofen; prioxicam; naproxen; celecoxib; and/or rofecoxib.

CLM What is claimed is:

. . . dual ET/AII receptor antagonists, and vasopeptidase inhibitors, an antiplatelet agent selected from GPIIb/IIIa blockers, P2Y.sub.12 antagonists, thromboxane receptor antagonists, and **aspirin**, an anti-thrombotic or anti-thrombolytic agent selected from thrombin inhibitors, alpha2-antiplasmin inhibitors, streptokinase, urokinase, and prourokinase, an anti-diabetic agent selected from biguanides, sulfonylureas, biguanide/glyburide combinations, aP2 inhibitors, and DP4 inhibitors, or an anti-inflammatory agent selected from cyclooxygenase inhibitors and **aspirin.**

IT **50-78-2**, Aspirin
(combination of factor Xa lactam inhibitor and of aspirin)

IT **50-78-2**, Aspirin
(combination of factor Xa lactam inhibitor and of aspirin)

RN 50-78-2 USPATFULL

CN Benzoic acid, 2-(acetyloxy)- (9CI) (CA INDEX NAME)




L28 ANSWER 35 OF 37 USPATFULL on STN

AN 2002:43590 USPATFULL

TI Lactam inhibitors of factor Xa and method

IN Stein, Philip D., Pennington, NJ, UNITED STATES
O'Connor, Stephen P., Newtown, PA, UNITED STATES
Shi, Yan, Flourtown, PA, UNITED STATES
Li, Chi, Randolph, NJ, UNITED STATES

PI US 2002025957 A1 20020228
US 6544981 B2 20030408

AI US 2001-874739 A1 20010605 (9) <--

PRAI US 2000-210384P 20000609 (60) <--

DT Utility

FS APPLICATION

LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2820

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Lactam inhibitors are provided which have the structure ##STR1##

including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and

and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 , R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.10a, 10.sub.11 and R.sub.12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-874739 A1 20010605 (9) <--
PRAI US 2000-210384P 20000609 (60) <--
DETD . . . combination with the compounds of the present invention include: GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban); P2Y.sub.12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747**); thromboxane receptor antagonists (e.g., ifetroban); **aspirin**; and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**
DETD . . . present invention include: prednisone; dexamethasone; enbrel; protien tyrosine kinase (PTK) inhibitors; cyclooxygenase inhibitors (including NSAIDs, and COX-1 and/or COX-2 inhibitors); **aspirin** ; indomethacin; ibuprofen; prioxicam; naproxen; celecoxib; and/or rofecoxib.
CLM What is claimed is:
. . . 6 wherein the additional therapeutic agent is an antiplatelet agent selected from GPIIb/IIIa blockers, P2Y.sub.12 antagonists, thromboxane receptor antagonists, and **aspirin.**

. . . The pharmaceutical composition of claim 6 wherein the additional therapeutic agent is an anti-inflammatory agent selected from cyclooxygenase inhibitors, and **aspirin.**

L28 ANSWER 36 OF 37 USPATFULL on STN
AN 2002:37917 USPATFULL
TI Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
IN Li, James J., Pennington, NJ, UNITED STATES
Tino, Joseph A., Lawrenceville, NJ, UNITED STATES
PI US 2002022637 A1 20020221
US 6469024 B2 20021022
AI US 2001-852565 A1 20010510 (9) <--
PRAI US 2000-203335P 20000511 (60) <--
DT Utility
FS APPLICATION
LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Tetrahydroisoquinoline analogs are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.

The tetrahdroisoquinoline analogs thereof have the structure ##STR1##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.3a, X.sub.1, X.sub.2, X.sub.3, X.sub.4, m and n are as described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2001-852565 A1 20010510 (9) <--

PRAI US 2000-203335P 20000511 (60) <--
SUMM . . . the compounds of the present invention include prednisone, dexamethasone, Enbrel, cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors such as NSAIDs, **aspirin**, indomethacin, ibuprofen, piroxicam, Naproxen, Celebrex, Vioxx), CTLA4-Ig agonists/antagonists, CD40 ligand antagonists, integrin antagonists, alpha4 beta7 integrin antagonists, cell adhesion inhibitors,. . .
SUMM . . . combination with the compounds of the present invention include GPIIb/IIIa blockers (e.g., abciximab, eptifibatide, tirofiban), P2Y12 antagonists (e.g., clopidogrel, ticlopidine, **CS-747** ), thromboxane receptor antagonists (e.g., ifetroban), **aspirin** , and PDE-III inhibitors (e.g., dipyridamole) with or without **aspirin.**

L28 ANSWER 37 OF 37 USPATFULL on STN
AN 2002:24279 USPATFULL
TI Lactam compounds and their use as inhibitors of serine proteases and method
IN Bisacchi, Gregory S., Ringoes, NJ, United States
Seiler, Steven M., Pennington, NJ, United States
Lawrence, R. Michael, Yardley, PA, United States
Sutton, Jr., James C., Princeton Junction, NJ, United States
Slusarchyk, William A., Skillman, NJ, United States
Zhao, Guohua, Princeton, NJ, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6344450 B1 20020205
AI US 2000-633751 20000807 (9) <--
RLI Continuation-in-part of Ser. No. US 2000-478632, filed on 6 Jan 2000
PRAI US 1999-119374P 19990209 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kifle, Bruck
LREP Rodney, Burton
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Lactam inhibitors are provided which have the structure ##STR1##

X is ##STR2##

wherein

Y is O or S and R.sup.4 is ##STR3##

R.sup.7O-- or R.sup.8

and R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, R.sup.7, and R.sup.8, are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants, and are inhibitors of tryptase and thus are useful in treating asthma. Methods for treating cardiovascular diseases associated with thromboses and for treating asthma and related diseases are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2000-633751 20000807 (9) <--
PRAI US 1999-119374P 19990209 (60) <--
SUMM . . . in combination with other antithrombotic or anticoagulant drugs

such as thrombin inhibitors, platelet aggregation inhibitors such as clopidogrel, ticlopidine or **CS-747**, warfarin, low molecular weight heparins, (such as Lovenox), GPIIb blockers/GPIIIa blockers, PAI-1 inhibitors such as XR-330 and T-686, inhibitors of. . . in combination with thromboxane receptor antagonists/thromboxane A synthetase inhibitors (such as picotamide), serotonin-2-receptor antagonists (such as ketanserin), fibrinogen receptor antagonists, **aspirin**, hypolipidemic agents (such as HMG-CoA reductase inhibitors for example pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, itavastatin (Nissan/Kowa), compounds disclosed in. . . and ACE/NEP inhibitors, for example omapatrilat and gemopatrilat), β-blockers (such as propranolol, nadolol and carvedilol), PDE inhibitors in combination with **aspirin**, ifetroban, picotamide, ketanserin or clopidogrel and the like.

=> d his

```
     (FILE 'HOME' ENTERED AT 06:18:37 ON 05 JUL 2005)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 06:18:48 ON 05 JUL 2005
L1             1 S US20040024013/PN OR (US2003-600266# OR WO2001-JP11201)/AP,PRN
L2         26955 S (SANKYO? OR UBE?)/PA,CS
               E ASAI F/AU
L3            78 S E3,E10
               E FUMITOSHI/AU
               E SUGIDACHI A/AU
L4            31 S E3,E5
               E ATSUHIRO S/AU
               E OGAWA T/AU
L5           776 S E3,E73
               E TAKETOSHI O/AU
               E INOUE T/AU
L6          1004 S E3-E5
               E INOUE TERU/AU
L7            66 S E6
               E TERUHIKO I/AU
L8             1 S E4
L9             5 S 2 ACETOXY 5 ALPHA CYCLOPROPYLCARBONYL 2 FLUOROBENZYL 4 5 6 7
               SEL RN L1

     FILE 'REGISTRY' ENTERED AT 06:22:54 ON 05 JUL 2005
L10            4 S E1-E4
L11            1 S L10 AND C20H20FNO3S AND 1/NC
L12            2 S 150322-43-3/CRN
L13            1 S 50-78-2
L14          508 S 50-78-2/CRN

     FILE 'HCAPLUS' ENTERED AT 06:24:24 ON 05 JUL 2005
L15           17 S L11 OR L12
L16           13 S CS747 OR CS 747 OR PRASUGREL OR LY640315 OR LY()(640315 OR 64
L17           21 S L9,L15,L16
L18        19865 S L13 OR L14
L19        27214 S ASPIRIN? OR (ACETYLSALICYLIC OR ACETYL SALICYLIC)()ACID OR AC
L20            7 S L17 AND L18,L19
L21            2 S L1-L8 AND L20
L22            7 S L20,L21
L23            4 S L22 AND (PY<=2001 OR PRY<=2001 OR AY<=2001)
L24            3 S L22 NOT L23
```

```
L25           5 S L21,L23

     FILE 'USPATFULL' ENTERED AT 06:31:05 ON 05 JUL 2005
L26          72 S L17
L27          64 S L26 AND (L18,L19)
L28          37 S L27 AND (PY<=2001 OR PRY<=2001 OR AY<=2001)

     FILE 'EMBASE' ENTERED AT 06:32:27 ON 05 JUL 2005
L29          24 S L17
L30          10 S L29 AND L18,L19
                E ASPIRIN/CT
                E E3+ALL
                E E2+ALL
L31       74966 S E1
L32          88 S ASPIRIN?/CT
L33          10 S L29 AND L31,L32
L34          10 S L30,L33
L35           0 S L34 AND PY<=2001

     FILE 'WPIX' ENTERED AT 06:34:03 ON 05 JUL 2005
L36           6 S L9/BIX OR L16/BIX
                E PRASUGREL/CN
L37           1 S E3
L38           4 S RA7RM2/DCN
L39           7 S L36,L38
L40        3676 S L19/BIX
                E ASPIRIN/DCN
                E E3+ALL
L41        2253 S E2 OR 0034/DRN
L42           2 S E4
L43           4 S E6
L44        1149 S E8
L45          16 S E10
L46           5 S L39 AND L40-L45
L47           1 S (2 ACETOXY 5 ALPHA CYCLOPROPYLCARBONYL 2 FLUROROBENZYL 4 5 6
L48           4 S L16/BI,ABEX,TI
L49           5 S L39,L47,L48 AND L40-L45
L50           5 S L46,L49
                SEL DN AN 1 3
L51           2 S L50 AND E1-E4

     FILE 'REGISTRY' ENTERED AT 06:41:40 ON 05 JUL 2005

     FILE 'HCAPLUS' ENTERED AT 06:42:02 ON 05 JUL 2005

     FILE 'WPIX' ENTERED AT 06:42:36 ON 05 JUL 2005

     FILE 'USPATFULL' ENTERED AT 06:44:24 ON 05 JUL 2005

=>
```